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I. INTRODUCTION 
 
I.1. The formation, prevention and treatment of cancer 
 
 I.1.1. General information 
 
Cancer is a leading cause of death worldwide, it accounted for nearly 8 million deaths in 2007 
and this number continues rising. Cancer can affect any tissue of the human body at all ages. 
One defining feature of cancer is the rapid and uncontrolled growth, invasion and spread of 
abnormal cells. By mortality worldwide, the most frequent types of cancer among males are 
lung, stomach, liver, colon-rectal, oesophagus and prostate cancer while among females they 
are breast, lung, stomach, colon-rectal and cervix cancer [WHO fact sheet N ° 297, 2008].  
Cancer progression is the consequence of the correlation between genetic and exogenous 
factors, including: physical carcinogens (such as ultraviolet and ironising radiation), chemical 
carcinogens (such as asbestos, tobacco smoke, aflatoxin and arsenic) and biological 
carcinogens (such as infections from certain viruses, bacteria or parasites) [Ames & Gold, 
1997]. Knowledge about interventions of cancer prevention, early detection, treatment and 
care becomes more extensive.  
 
 I.1.2. Cancer formation, prevention and treatment 
 
Many different types of cancers are diagnosed. Hanahan and Weinberg suggested there are six 
capabilities which are shared in common by most if not all types of human tumours (Figure 
1): self-sufficiency in growth signals, insensitivity to growth-inhibitory signals, evasion of 
apoptosis, limitless replicative potential, sustained angiogenesis, and tissue invasion and 
metastasis [Hanahan & Weinberg, 2000].  
 I. INTRODUCTION 
  
 
 
2 
                               
Figure 1: Acquired capabilities of cancer. Most if not all cancers have acquired the same set of 
functional capabilities during their development, although through various mechanistic strategies. (Adopted from 
Hanahan & Weinberg, 2000) 
 
The transformation from normal human cells into malignant tumours is a multi-step process. 
At least three separate stages with certain differences at the molecular and biological level are 
involved: initiation, promotion and progression [Pitot, 1993]. Under the influence of 
endogenous and exogenous factors, initiation stage spontaneously results from an irreversible 
genetic damage. Initiated cells might be repaired or removed through apoptosis before they 
can evolve into a malignancy. The subsequent stage, promotion, is a reversible step resulting 
in the development of numerous benign lesions. The progression of benign tumours to 
malignant cancers occurs irreversibly spontaneously at a low frequency. During progression, 
additional genetic damage appears and the cell shows characteristics of a fully transformed 
phenotype, including invasion and metastasis.  
Cancer prevention can be divided into three stages: primary, secondary and tertiary. Primary 
prevention refers to the complete prevention through inhibition of exposure to carcinogenic 
factors. Secondary prevention involves early detecting and the appropriate retarding the 
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disease progress after diagnosis. After a suitable therapy, tertiary prevention represents an 
attempt to prevent local recurrences, invasion and metastasis [De Flora et al., 2001]. 
Chemoprevention of cancer is a means of cancer control in which the occurrence of the end 
stages of cancer (invasion and metastasis) are prevented by administration of one or several 
natural or synthetic compounds [Sporn & Suh, 2000]. Chemopreventive interventions with 
agents targeted in order to block, arrest or even reverse specific stages of carcinogenic process 
is really a promising strategy for cancer prevention. Natural products which have multiple 
mechanisms of action became a vast source of potent chemopreventive agents [Shureiqi et al., 
2000].  
Nowadays a variety of therapeutic options for cancer are available. Besides standard 
modalities, including surgery, chemotherapy and radiation therapy, other treatment methods 
have been developed, such as immunotherapy, targeted therapy, hormonal therapy, gene 
therapy, adjuvant therapy, cancer vaccine therapy and cancer complementary and alternative 
medicine.  
 
I.2. Apoptosis: a mechanism for cancer prevention and treatment 
 
I.2.1. General information 
 
Cell death can occur by many morphological, biological and functional distinct pathways, 
including apoptosis, autophagy, necrosis and mitotic catastrophe [Galluzzi et al., 2007]. The 
term “apoptosis” had been coined and was first introduced in a publication in 1972 by Kerr, 
Currie and Wyllie [Kerr et al., 1972] to describe a cell death process leading to controlled 
cellular self-destruction characterized by defined morphological changes, including cellular 
shrinkage, chromatin condensation, loss of nuclear membrane integrity, plasma membrane 
blebbing and eventually apoptotic body formation. Apoptosis plays a fundamental role for the 
development of all multicellular organisms whereby unwanted cells which are functionally 
redundant or potentially detrimental to the organism are eliminated. This mode of cell death is 
significant for variety of biological processes, such as morphogenesis of embryonic tissues as 
well as homoeostasis maintenance of architecture of adult organs and tissues, regulation and 
function of the immune system and removal of defect cells. Therefore inappropriate 
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regulation and function of apoptosis bring severe consequences. Failure of apoptosis can 
cause cancer, autoimmune diseases and spreading of viral infections, while excessive 
apoptosis results in neurodegenerative/neurodevelopmental disorders, acquired immune 
deficiency syndrome (AIDS) and ischaemic diseases [Rudin & Thompson, 1997]. Apoptosis 
has been found to occur in all multicellular animals studied so far [Ameisen, 2002], such as 
cnidaria [Böttger & Alexandrova, 2007], nematodes [Liu & Hengartnet, 1999], insects 
[Richardson & Kumar, 2002], amphibians [Nakajima et al., 2005] and mammals [Ranger et 
al., 2001].  
 
I.2.2. Caspases activation 
 
In mammalian cells, caspases, a family of cysteinyl aspartate-specific proteases, are the 
central regulators of apoptosis [Nicholson & Thornberry, 1997]. So far, 14 members of the 
caspase family have been identified in mammals. Based on their function in the proteolytic 
caspase cascade, they can be classified in three groups: initiator caspases, including caspase-2, 
-8, -9 and -10; effector caspases, such as caspase-3, -6, and -7 and caspases involved in 
control of inflammation, including caspase-1, -4, -5, -11, -12, -13, -14 [Nuñez et al., 1998]. 
Caspases are synthesized in the cell as inactive zymogens, the procaspases that become 
mature by the autoproteolytic cleavage or the cleavage by other caspases. Initiator caspases 
are activated by a spectrum of apoptotic stimuli. Whereas effector caspases possess short 
prodomains, initiator caspases possess long prodomains containing either a death effector 
domains (DED) (in procaspase-8 and -10) or a caspase recruitment domains (CARD) 
(procaspase-2 and -9). Subsequently, activated initiator caspases can cleave and activate an 
overlapping set of effector caspases, which in turn execute apoptosis by cleaving cellular 
proteins following specific Asp residues.  
There are two main pathways of caspase activation: ligation of death receptors following 
extracellular triggering (extrinsic apoptosis pathway) and release of cytochrom c from 
mitochondria following intracellular signals (intrinsic apoptosis pathway). In addition, two 
other apoptotic pathways are emerging: endoplasmic reticulum stress-induced apoptosis and 
caspase-independent apoptosis [Vermeulen et al., 2005]. 
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I.2.3. The death receptor-induced apoptosis pathway 
          
 
Figure 2: Death receptor pathway. Death factors such as FasL and TNF trigger apoptosis by binding 
on ‘death receptors’ such as Fas and TNFR-1. The death receptors recruit procaspase-8 by means of an adaptor 
protein, FADD. After cleavage the mature caspase-8 then directly activates caspase-3 or cleaves Bid. tBid 
interacts with Bax and Bak, then stimulates the release of cytC by the mitochondria and the activation of 
caspase-9. Effector caspases are activated leading to the degradation of cellular proteins necessary to maintain 
cell survival and integrity. Activation of caspases is negatively regulated at the receptor level by FLIP, which 
block caspase-8 activation, and at the mitochondria by BCL-2 family proteins and IAPs. 
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The death-receptor pathway is triggered by members of the death-receptor superfamily which 
are cell surface receptors that transmit apoptotic signals after ligation with respective ligands. 
Death receptors belong to the tumour necrosis factor receptor (TNFR) gene superfamily, 
including Fas/CD95, TNFαR, DR3, and the TRAIL receptors DR4 and DR5. All of them 
possess cysteine-rich extracellular domains and a cytoplasmic death domain (DD) 
[Ashkenazi, 2002]. The DD is crucial for the transduction of the apoptotic signal. Death 
receptor ligands initiate signaling via receptor oligomerization in the cell membrane, which 
leads to the recruitment of specialized adaptor proteins via DD interactions and activation of 
caspase cascades. 
The recruitment of adaptor proteins results in the formation of a death inducing signalling 
complex (DISC). In this complex, adaptor protein such as Fas-associated protein with DD 
(FADD) interacts via its own DD with the DD of Fas. In addition, adapter protein FADD also 
contains a death effector domain (DED) which is homologous to the domain found in 
caspase-8. Therefore, binding of FADD to Fas receptor results in the recruitment and auto-
activations of caspase-8. The activated caspase-8 stimulates apoptosis through two pathways. 
Activated caspase-8 can directly cleave and activate downstream effector caspases, which in 
turn subsequently execute apoptosis. Alternatively, it can cleave Bid, a Bcl-2 family member. 
Truncated Bid (tBid) translocates to mitochondria, and then the release of cytochrome c is 
induced and caspase-9 is activated. Activated caspase-9 initiates a caspase cascade by 
activating downstream effector caspases [Ashkenazi & Dixit, 1998; Luo et al., 1998]. 
TNF-α and DR-3L can deliver pro- or anti-apoptotic signals. TNF-α, unlike FasL and TRAIL, 
is generally a poor inducer of cell death. Interaction of TNF-α with TNFαR might activate 
NF-κB pathway [Karin & Lin, 2002]. NF-κB induces expression of several anti-apoptotic 
genes, including Bcl-2, FLIP and XIAP. FLIP inhibits the activation of caspase-8. XIAP 
directly binds and inhibits effector caspases.  
 
I.2.4. The mitochondria apoptosis pathway 
 
The intrinsic apoptotic pathway is triggered by various death signals originating from inside 
the cell, including DNA damage, starvation and stress signals induced by irradiation and 
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chemotherapeutic drugs [Wang et al., 2001]. In this pathway, various apoptosis-inducing 
signals suddenly induce mitochondrial outer membrane permeabilization (MOMP) [Green, 
2004]. It results in the release of pro-apoptotic proteins normally found in the space between 
inner and outer mitochondrial membranes into cytoplasm, including cytochrome c (cytC), 
HtrA2/Omi, Smac/Diablo, apoptosis-inducing factor (AIF) and endonuclease EndoG. MOMP 
can also cause the metabolic or functional defect in the mitochondria which leads to the loss 
of the biochemical homeostasis of the cell and cell death. Cytochrome c after released from 
mitochondria assembles with the adaptor molecule APAF-1 and triggers apoptosome 
formation. Only the caspase-9 bound to apoptosome can cleave and activate downstream 
effector caspases, which in turn execute apoptosis. XIAP molecules bind and inhibit caspase-
3 via their BIR domains. This inhibition is relieved by Smac/Diablo that binds to BIR 
domains of XIAP molecules and replaces caspases from XIAP and enables their activation 
[Verhagen et al., 2000]. It has been known that HtrA2 protein, like Smac/Diablo, can prevent 
XIAP inhibition of active caspase-3 and promote cell death [Verhagen et al., 2002]. The 
translocation of AIF results in caspase-independent chromatin condensation and DNA 
fragmentation [Susin et al., 1999]. EndoG induces also caspase-independent DNA 
fragmentation once released from the intermembrane space [Li et al., 2001]. Roles of AIF and 
EndoG in apoptosis indicate that apoptosis can proceed without caspases. 
The mitochondrial permeability and the release apoptogenic molecules are regulated by Bcl-2 
protein family. Bcl-2 was discovered as an oncogene that prevents apoptosis rather than 
promotes proliferation [Vaux et al., 1988]. Up to date, at least members of Bcl-2 protein 
family have been identified which are characterized by the presence of the conserved 
sequence motif, the so-called Bcl-2 homology domains [Cory & Adams, 2002]. Besides Bcl-
2, subfamily of pro-survival proteins consists of Bcl-XL, Bcl-w, A1, and Mcl-1 which all 
possess BH1, BH2, BH3 and BH4 domains. There are two subfamilies of pro-apoptotic 
proteins: the Bax and the BH3-only subfamilies. Members of Bax subfamily, including Bax, 
Bak, Bok, possess BH1, BH2 and BH3 domains but proteins of BH3-only subfamily, such as 
Bik, Bad, Bid, Bim, Bmf, Hrk, Noxa, and Puma, have only the short BH3 motif. Cellular 
homeostasis might depend on the balance between the pro-survival and BH3-only proteins.  
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Figure 3: Mitochondrial pathway. The intrinsic pathway occurs when various apoptotic stimuli 
trigger the release of apoptogenic factors such as cytC (independently of caspase-8 activation), AIF, or 
Smac/Diablo from the mitochondrial inter-membrane space. The release of cytC into cytoplasm triggers caspase-
3 activation through formation of the cytC/Apaf-1/caspase-9-containing apoptosome complex. The death-
receptor and mitochondrial pathway can be interconnected at different levels. 
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Activated in response to oncogene activation or DNA damage, p53, a tumour suppressor 
protein, induces the expression of pro-apoptotic proteins, such as Bax, Noxa and Puma or 
represses the transcription of pro-survival genes, such as bcl-2, bcl-XL or surviving [Chipuk & 
Green, 2006].  
 
 I.2.5. Apoptosis: a novel target for the chemoprevention of cancer 
 
A variety of chemopreventive agents has been shown to trigger apoptosis in pre-malignant 
and malignant cells in vitro and in vivo [Sun et al., 2004]. Some chemopreventive agents, 
such as triterpenoids and retinoids induce the expression of death receptors [Sun, 2005]. 
Several other cancer chemopreventive agents can induce apoptosis via mitochondrial pathway 
by proceeding through the regulation of Bcl-2 family members or through induction of the 
mitochondrial permeability transition [Hail, 2005]. The strategy to use chemopreventive 
agents that induce apoptosis might be an effective means in order to abate or control cancer. 
 
I.3. Mushroom as a source of anti-tumour agents 
 
 I.3.1. Medical mushrooms with anti-tumour and immuno-
modulatory activities 
 
Many edible and non-edible mushrooms have long been used worldwide, especially in 
oriental countries, for medical purposes. Medical mushrooms have become more and more 
widely used for prevention and treatment of a variety of diseases, including cancer. In the last 
decades, medical mushrooms have been intensively investigated in vivo and in vitro for 
medical properties. Wasser has indicated that at least 651 species of mushroom classes 
Hetero- and Homobasidiomycetes contain anti-tumour or immunostimulatory compounds 
[Wasser, 2002]. Pretrova et al. demonstrated that fungal metabolites can be used as novel 
cancer chemopreventive agents [Petrova et al., 2008]. Until now, several pharmaceutical 
products have been derived from medical mushrooms: Ganopoly -polysaccharide extract from 
Ganoderma lucidum and Cordyceps sinensis, Lentinan from fruit bodies of Lentinula edodes, 
Schizophyllan from liquid cultured broth product of Schizophyllum commune, PSP 
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(polysaccharide peptide) and PSK (or Krestin, protein-bound polysaccharide) from cultured 
mycelial biomass of Coriolus versicolor, Grifon-D from Grifola frondosa, Mesima from 
Phellinus linteus, etc. 
Selected examples of medical mushrooms with anti-tumour and immuno-modulatory 
activities were listed in Table 1. Subsequently evidences about pharmaceutical activities of 
some of medical mushrooms were analyzed.  
Agaricus blazei is an edible mushroom, native to Brazil, widely cultivated for its culinary and 
medical uses. This mushroom has been used in folk medicine against various diseases, such as 
chronic hepatitis, diabetes, arteriosclerosis, hyperlipidaemia and cancer [Wasser & Weis, 
1999]. Its immuno-modulatory property has shown in many in vitro and in vivo studies but the 
molecular mechanisms and chemical substances involved in its pharmaceutical activities 
remain unclear [Firenzuoli et al., 2008].  Extracts from A. blazei have been reported to have 
anti-tumour [Mizuno et al., 1999; Ohno et al., 2001; Takaku et al., 2001; Kimura et al., 2004] 
, anti-angiogenic [Kimura et al., 2004] and anti-mutagenic effects [Delmanto et al., 2001; 
Guterrez et al., 2004]. It has been reported that a 10% powdered A. blazei diet has a 
chemopreventive influence on the promoting phase of the rat chemical hepatocarcinogenesis 
process [Pinheiro et al., 2003]. Aqueous extract of A. blazei, induced a specific G2/M phase 
arrest through cdc2 and cyclin B1 and triggered apoptosis via the regulation of Bax and the 
activation of caspase-3 in human gastric epithelial AGS cells [Jin et al., 2006]. In another 
study, people from the same group demonstrated that apoptosis induced by aqueous extract of 
A. blazei was associated with the PI3K/Akt pathway, the reduction of Bcl-2 levels, caspase-3 
activation and PARP degradation [Jin et al., 2007].  
Coriolus versicolor has been commonly used in China. Many reports based on in vivo and in 
vitro preclinical and clinical studies have revealed the therapeutic values of extracts from C. 
versicolor in the treatment of cancer [Chu et al., 2002]. The chemopreventive potential of 
polysaccharides from C. versicolor and Ganoderma lucidum was demonstrated using 
biomarkers for carcinogenesis [Kim et al., 1999]. Polysaccharide peptides isolated from C. 
versicolor, such as PSP and PSK, have long been shown to manifest immuno-modulatory 
anti-tumour effects. PSP was able to diminish side effects of radiotherapy and chemotherapy; 
therefore, it might be used as adjunct for cancer treatment [Ng, 1998]. Extracts from this 
mushroom were found to selectively and dose-dependently inhibit the proliferation of various 
tumour cell lines via arrest of cell cycle and induction of apoptosis [Hsieh et al., 2006; 
Jeménez-Medina et al., 2008].  
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Inonotus obliquus is a white rot fungus, widely distributed over Europe, Asia and North 
America. Its imperfect form, sclerotium, called ‘Chaga’ has been used as a folk medicine in 
Russia and western Siberia since the 16th century [Saar, 1991]. Recently, many bioactive 
compounds such as polyphenols [Cui et al., 2005] and triterpenoids, including lanosterol, 
inotodiol and trametenolic acids [Nakata et al., 2007] have been found in ‘Chaga’. These 
compounds exhibited various biological activities, such as anti-tumour, anti-oxidant [Song et 
al., 2008], anti-inflammatory activites [Kim et al., 2007]. 3,4-Dihydroxybenzalacetone, one of 
the most potent polyphenol derived from ‘Chaga’, could enhance apoptosis and inhibit 
proliferation and invasion through the inhibition of NF-κB activation and NF-κB-regulated 
gene expression [Sung et al., 2008]. It has been reported that aqueous extract from ‘Chaga’ 
induced the growth inhibition, G0/G1 phase arrest and apoptosis in human hepatoma HepG2 
cells [Youn et al., 2008]. This phenomenon was closely associated with the down-regulation 
of p53, pRb, p27, cyclins D1, D2, E, cyclin-dependent kinase (Cdk) 2, Cdk 4 and Cdk6 
expression. 
Ganoderma mushrooms have been used in oriental countries as medical remedy for longevity 
and health promotion since centuries [Paterson, 2006]. Extracts and even substances from 
Ganoderma mushrooms rapidly emerged as promising immunotherapeutic agents in treatment 
of many diseases. 
Ganoderma lucidum was the most extensively studied species and has been used to prevent or 
treat various human diseases [Sliva, 2006]. Recent studies showed that both the 
polysaccharides fraction and the triterpene fraction of G. lucidum possessed anti-tumour and 
immuno-modulatory properties through mechanisms involving the inhibition of activities of 
replicative DNA polymerases [Mizushina et al., 1998], the stimulation of cytokine release and 
apoptosis [Wang et al., 1997] and the inhibition of angiogenesis and invasion [Lin & Zhang, 
2004]. Previous reports revealed that G. lucidum extract inhibited the cell proliferation and 
induced apoptosis in a dose- and time-dependent manner in several cancer cell lines [Hong et 
al., 2004; Hu et al., 2002; Müller et al., 2006]. Differentiation protein and gene expressions 
upon treatment of extracts from G. lucidum have already investigated to get a deeper look into 
its molecular mechanisms [Ma et al., 2008; Cheng et al., 2007].  
Crude extracts from another species, G. tsugae, have been demonstrated to stimulate splenic 
natural killer cell activity and serum interferon production in mice [Won et al., 1992]. It has 
been reported that a lanostanoid ester glucoside and a steroid, both isolated from G. tsugae, 
mediate their cytotoxicity through cell cycle regulation and apoptosis [Gan et al., 1998].  
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Mushroom scientific name Potential compounds References 
Agaricus blazei Murr. (1→6)-β-D-glucan, heteropolysaccharides, polysaccharide-protein complex [Itoh et al., 1994; Kim et al., 2005] 
Agrocybe aegerita (Brit.) Sing. lectin [Zhao et al., 2003] 
Auricularia auricula-judae (Bull.) 
Wettst. (1→3)-β-D-glucan [Misaki et al., 1981] 
Coriolus versicolor (L.:Fr.) Quel. polysaccharide peptides [Ng, 1998] 
Flammulina velutipes (Curt.:Fr.) 
P.Karst. glycoprotein [Ohkuma et al., 1982] 
Fomes fomentarius (L.:Fr.) Fr. exopolysaccharide [Chen et al., 2008] 
Ganoderma applanatum (Pers.) Pat. polysaccharide [Sasaki  et al., 1971] 
Ganoderma lucidum (Curt.:Fr.) P. 
Karst. β-D-glucans, heteropolysaccharides, glycoproteins 
[Hong et al., 2004; Hu et al., 
2002; Müller et al., 2006] 
Ganoderma tsugae Murr. polysaccharide-protein complex [Zhang et al., 1994] 
Grifola frondosa (Dick.:Fr.) S. F. Gray (1→3)-β-D-glucan  [Suzuki et al., 1989] 
Hericium erinaceus (Bull.:Fr.) Pers. polysaccharide [Wang et al., 2001] 
Inonotus obliquus (Pers.:Fr.) Bond.et 
Sing. polysaccharide [Song et al., 2008] 
Lentinula edodes (Berk.) Pergler (1→3)-β-D-glucan with (1→6)-β-D-glucosyl branches [Zhang & Cheung, 2002] 
Phellinus linteus (Berk.&Br.) Teng polysaccharides [Sasaki  et al., 1971] 
Phellinus rimosus (Berk.) Pilat ethyl aceate, methanol and aqueous extracts [Ajith & Janardhanan, 2003] 
Pleurotus ostreatus (Jacq.:Fr.) Kumm. β-glucan, heteroglucan [Gern et al.,2008] 
Poria cocos Wolf β-glucan, heteropolysaccharide [Wang et al., 2004; Jin et 
al., 2003] 
Schyzophyllan commune Fr.:Fr. (1→3)-β-D-glucan with (1→6)-β-D-glucosyl branches [Usui et al., 1994] 
Tremella fuciformis Berk. glucuronoxylomannans [Kiho  et al., 1994] 
Tricholoma mongolicum Imai lectins [Wang et al., 1996] 
Volvariella volvacea (Bull.:Fr.) Sing. β-glucan [Kishida et al., 1989] 
 
Table 1: Selected examples of medical mushrooms with anti-tumour and immuno-modulatory activities 
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The anti-tumour and immuno-modulatory effects of a perennial representative of Ganoderma 
genus, G. applanatum, have been also demonstrated in mice [Jeong et al., 2008]. 
Phellinus is another large and widely distributed genus. In oriental folk medicine, several 
species of Phellinus were known to improve health and to prevent and remedy various 
diseases. In the last decade, many pharmacological properties of Phellinus species have been 
elucidated.   
Extract from P. igniarius has been demonstrated to possess anti-mutagenic activities, likely 
by inducing QR and GST activities and increasing GSH level [Shon & Nam, 2001]. It has 
been reported that the butanol extract of Phellinus igniarius induced relaxation of the 
phenylephrine-procontracted rat aorta in a dose-dependent manner, and its effect is abolished 
by the removal of functional endothelium [Kang et al., 2006]. In addition, ethanol extract of 
P. igniarius has been shown to exert anti-proliferative and anti-metastatic effects on human 
hepatocarcinoma SK-Hep-1 cells and rat heart vascular endothelial cells, partly by 
suppressing the secretion of matrix metalloproteinase-2 and vascular endothelial growth 
factor [Song et al., 2008]. 
Ajith and Janardhanan pointed out that ethyl acetate, methanol and aqueous extracts of P. 
rimosus showed remarkable anti-inflammatory, anti-oxidant and anti-tumour effects [Ajith & 
Janardhanan, 2001; Ajith & Janardhanan, 2002; Ajith & Janardhanan, 2003]. They also 
suggested that aqueous extract of P. rimosus possessed significant chemopreventive 
properties [Ajith & Janardhanan, 2006]. 
P. linteus is another non-edible mushroom which gained important medical usage since 
centuries in China and Korea. Recently, P. linteus has been paid great attention due to its anti-
tumour effect [Han  et al., 2006; Guo et al., 2007; Sliva et al., 2008] and other medical values, 
including antioxidant [Song et al., 2003], anti-inflammatory [Kim et al., 2004], anti-microbial 
activities [Yeo et al., 2007]. Studies of different groups have shown that extracts of P. linteus 
rendered several human cancer cell lines susceptible to apoptosis [Choi et al., 2004; Li et al., 
2004; Zhu et al., 2007]. Furthermore, it has been reported that P. linteus was able to enhance 
activities of doxorubixin, a conventional chemotherapeutic drug [Collins et al., 2006]. These 
evidences indicated that P. linteus might be an alternative anti-tumour agent or a synergizer 
for existing anti-tumour drugs [Zhu et al., 2008]. 
Although many pharmaceutical properties, emphatically the anti-tumour properties, of several 
medical mushrooms were extensively investigated, sufficient scientific studies have not been 
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performed to characterize the mechanisms by which medical mushrooms exert their activities. 
Moreover, the majority of these observations often lack standardization and are still based on 
phenomenology [Borchers et al., 2008]. So considerable understanding in molecular level 
remains to be determined. 
 
I.3.2. Phellinus pachyphloeus (Pat.) Pat. 
 
A.  
 B.  
C.  D.  
E.  F.  
 
Figure 4: Phellinus pachyphloeus.  A. Natural perennial ungulate basidiocarp. B. Layers of tubes 
separate from tissue layer. C. Hymenial setae through scanning electron microscope (SEM). D. Basidiospore 
through SEM. E. Formation of the immature fruit body on potato dextrose agar medium. F. Formation of 
cicatricial, immature fruit body on sawdust culture medium. 
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Phellinus pachyphloeus (Pat.) Pat. is a wood-decaying polypore macro-fungus species; 
belongs to the family Hymenochaetaceae of Basidiomycetes: lives on both deadwood and 
living trees, on fern roots, flowering plants, specially Fagaceae, Moraceae, Euphobiaceae and 
Mangiferaceae; and causes white rot [Larsen & Cobb-Poulle, 1990; Wagner & Firscher, 
2002]. This species is abundant and widely distributed. Basidiocarp of this species is up to 65 
× 125 × 50 cm, applanate to ungulate, sessile and usually thick (as depicted in Figure 4. A, B). 
Distinct structures for this species are the up-to-300 × 17-µm dark ferruginous tramal setal 
hyphae and the sharp-pointed hymenial setae with straight tips (Figure 4.C). As shown in 
Figure 4. E, F, we were successful in cultivating this species on potato dextrose agar medium 
and on sawdust culture medium and in both medium, immature fruit body were formed. The 
medicine values of its related species, such as Phellinus linteus or Inonotus obliquus, were 
well-documented, as remarked above. Water-soluble extract of P. pachyphloeus is 
increasingly used to treat a wide variety of disease processes. It therefore became necessary to 
attempt to determine its medical properties. 
 
I.4. miRNA 
 
 I.4.1. General information 
 
Cells contain numerous classes of small RNAs which mediate gene regulation and function 
for several pathways for gene silencing [Chu & Rana, 2007]. Small RNAs can be divided into 
different groups, including microRNAs (miRNAs), small-interfering RNAs (siRNAs), trans-
acting siRNAs (tasiRNAs), small-scan RNAs (scnRNAs), repeat-associated siRNAs 
(rasiRNAs) and Piwi-interacting RNAs (piRNAs). One major class of small RNAs - miRNAs 
- was first introduced in 2001 [Lagos-Quintana et al., 2001; Lau et al., 2001; Lee & Ambros, 
2001]. miRNAs are endogenous ~22-25 nt RNAs that play key regulatory roles by targeting 
mRNAs for cleavage or translational repression. Currently, hundreds of miRNAs have been 
identified in several metazoans by cloning or bioinformatics and this number is still 
increasing.  
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 I.4.2. Genomics of miRNAs 
 
Many miRNA genes are identified in clusters in the genome that can be transcribed as multi-
cistronic primary transcripts [Bartel, 2004]. The miRNAs within a genomic cluster are often 
related to each other. The miRNA genes are located in intergenic regions, introns of non-
coding genes, introns of coding genes in the sense or anti-sense orientation and in exons of 
non-coding genes [Rodriguez et al., 2004]. Many of miRNAs are evolutionarily conserved 
though the copy number of miRNA genes can vary among orthologs. The let-7 miRNA 
family has four members in Caenohabditis elegans, 15 in human but only one in Drosophila 
melanogaster [Aravin et al., 2003; Lim et al., 2003; Pasquinelli et al., 2000].  
Many modern approaches, including Northern blotting, microarray, real-time RT-PCR and in 
situ hybridisation have been used to identify miRNA expression profiles. Expression of 
miRNAs might be specific for a certain development stage or for a distinct tissue or cell type. 
 
 I.4.3. Biogenesis of miRNAs 
 
Biogenesis of miRNAs is a multi-step process. miRNAs are transcribed by RNA polymerase 
II (Pol II) as pri-miRNAs, precursor molecules with 3’ poly-A tails and 5’ capping structures. 
These long transcripts are then cleaved by Drosha-DGCR8 complex to produce pre-miRNAs, 
~ 70 nt stem-loop precursors with a 5’ phosphate end and a 2-nt 3’ overhang. Subsequently, 
pre-miRNAs are transported through nuclear pores into the cytoplasm by Ran-GTP and the 
export receptor Exportin-5. Pre-miRNAs are then processed by Dicer to produce ~ 22 nt 
duplexes of mature miRNA and an miRNA passenger strand (miRNA/miRNA*) with 2-nt 3’ 
overhang. Following processing, the miRNA duplex is loaded into miRNA-induced silencing 
complex (miRISC). During RISC assembly only one strand of the miRNA/miRNA* duplex 
might be incorporated, always the one whose 5’ end is less tightly paired, while the other one 
is degraded [Snøve & Rossi, 2006]. 
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Figure 5: miRNA biogenesis. Primary miRNA transcripts are recognized and cleaved in the nucleus by 
the RNase III enzyme Drosha, resulting in hairpin precursors named pre-miRNA. Pre-miRNA is exported from 
the nucleus to the cytoplasm by Exportin-5 and is further processed by another RNase enzyme named Dicer, 
resulting in a ~ 22 nt duplex. Only one strand of this duplex is incorporated into a RNA induced silencing 
complex (RISC). (Adopted from Snøve & Rossi, 2006). 
 
I.4.4. Mechanism of miRNA-mediated gene regulation 
 
Once incorporated into miRISC, miRNA can recognize its target mRNA at the 3’ UTR and 
down-regulate gene expression by repressing protein translation or by facilitating mRNA 
degradation and sequestrating mRNA to storage compartments. At least three models for the 
mechanism of miRNA-mediated gene silencing have been suggested. The first possible 
mechanism proposes a post-initiation repression mechanism primarily due to ribosome drop 
off during elongation of translation [Petersen et al., 2006]. After ribosomes are removed, 
miRSC containing transcripts locate to processing bodies (P-bodies) for storage or RNA 
destruction. The second model indicates that upon the regulation of miRNA, the mRNA 
translation is inhibited at the initiation step. Human let-7 miRNA inhibits translation initiation 
of its mRNA target in an m7G cap-dependent manner [Pillai et al., 2005]. Kiriakidou et al. 
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proposed that Agonaute protein 2 repressed the translation initiation by binding to the m7G 
cap of mRNA targets, therefore likely avoiding the recruitment of eIF4E, a translation 
initiation factor [Kiriakidou et al., 2007]. In another study, it has been shown that human 
RISC associated with a multi-protein complex containing eIF6, a ribosome-associated protein 
known to prevent the assembly of the 80S ribosome. The third model has been found by 
Bagga and colleagues [Bagga et al., 2005]. They revealed that mRNAs containing partial 
miRNA complementary sites can be targeted for degradation in vivo.  mRNA decay might be 
caused by the accelerated deadenyltation [Yu et al., 2005]. mRNA targets and miRISC after 
the translation repression are localized to P-bodies [Liu et al., 2005].  
Any miRNA might target different mRNAs and any mRNA might be targeted by several 
distinct miRNAs. Potential miRNA targets have been predicted and identified by 
bioinformatics approaches [Lewis et al., 2003]. These data should be further validated by 
experiments. 
 
 I.4.5. Biological functions of miRNAs 
 
Up to date, functions of only a few miRNAs have been identified. miRNAs involve in 
numerous biological processes and have crucial regulatory functions. In C. elegans, miRNAs 
affect the developmental timing [Moss et al., 1997] and the asymmetric expression of 
chemoreceptors in embryos [Chang et al., 2004]. miRNAs have been shown to suppress 
apoptosis, induce cell proliferation [Brennecke et al., 2003] and regulate fat metabolism in D. 
melanogaster [Xu et al., 2003]. In Mus musculus, miRNAs have been found to regulate 
developmental patterning [Yekta et al., 2004], proliferation and differentiation of several cell 
type [Chen, 2004 et al.; Chen et al., 2006], insulin secretion [Poy et al., 2004] and 
spermatogenesis [Yu et al., 2005]. Human miRNAs have been demonstrated to regulate 
adipocyte differentiation [Esau et al., 2004], mediate antiviral defence [Lecellier et al., 2005].  
 
 I.4.6. miRNAs and cancer 
 
Recent studies support the tight connection of miRNAs with the initiation and progression of 
human malignancies. Calin et al. have been first indicated the relation of miRNAs to cancer 
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[Calin et al., 2002].  They showed that both miR15 and miR16 genes lie in a 30-kb region at 
chromosome 13q14 and are frequently down-regulated or even deleted in patients with B cell 
chronic lymphocytic leukaemia, mantle cell lymphoma, multiple myeloma or prostate 
cancers. Surprisingly, a large number of miRNAs is located at fragile sites and cancer-
associated genomic regions [Calin et al., 2004].  It has been shown that miRNAs behave as 
tumour suppressor genes and oncogenes in many types of cancer [Zhang et al., 2007] and 
miRNA expression profiles might classify tumours [Lu, 2005] and predict the clinical 
outcome for patients [Calin et al., 2006]. Normal levels of miRNAs with the tumour 
suppressor function prevent uncontrolled cell proliferation. Examples of this group are miR-
15a, miR16 [Cimmino et al., 2005], and let-7 [Yanaihara et al., 2006]. The oncogene 
miRNAs promote tumour development by negatively inhibiting tumour suppressor genes or 
genes that control cell differentiation or apoptosis. The miRNAs that belong to miR-17-92 
cluster are over-expressed in several tumours, such as small-cell lung cancer and human B-
cell lymphomas [He et al., 2005; Hayashita et al., 2005]. The additional examples of 
oncogenic miRNAs are miR-21 [Iorio et al., 2005], miR-106a [Volinia et al., 2006], miR-155, 
miR-372 and miR-373 [Voorhoeve et al., 2006]. Increasing knowledge of regulatory 
functions of miRNAs might lead to promising diagnostic and therapeutic strategies. 
 
I.5. Aims of the study 
 
Aqueous extracts of the mushroom are a source containing highly promising anti-tumour and 
immuno-modulatory compounds. The genus Phellinus whose all members are perennial has 
been used in oriental countries to prevent and treat many diseases since centuries. The species 
Phellinus pachyphloeus Pat. (Pat.) is widely distributed and has also long been used for 
medical purposes in eastern traditional folk medicine and ethno-pharmacology. Mechanisms 
of anti-tumour, immuno-modulatory and other properties of medical mushrooms in general 
and P. pachyphloeus in particular are only partially examined and remain to be fully 
ascertained. Therefore, the aim of this study was to elucidate molecular mechanisms 
responsible for anti-tumour and immunostimulatory properties in human leukaemia cell line 
HL-60 upon treatment with water-soluble extract of P. pachyphloeus.  
Like starting studying other natural products, before developing an understanding about these 
mechanisms, we first sought to clarify whether the aqueous extract of P. pachyphloeus 
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possessed cytotoxic and anti-proliferative effects and whether the metal content of this extract 
might play a role in its activities. Apoptosis induction might involve in these mechanism thus 
one purpose of this study was to investigate in case apoptosis is trigged by our mushroom 
extract by valuable tools, such as FACS and ‘DNA laddering’ analysis. Apoptosis can occur 
via two main pathways, including the mitochondrial and the death-receptor pathway. In order 
to determine which pathway involves in apoptosis, the activation of the caspase cascade and 
the expression of other apoptotic/anti-apoptotic regulatory proteins were examined. 
Proteomics help to see behind the curtain the highly regulated network of protein expression, 
protein modifications and protein interactions. Therefore, the investigation on the differences 
on the protein level in human leukaemia HL-60 cells upon the treatment of our mushroom 
extract and the identification of apoptosis-associated proteins might provide an insight into 
the apoptotic process.  
Another goal of this thesis entails an investigation into miRNA expression in human 
leukaemia HL-60 due to treatment of our mushroom extract. In pursuit of this purpose, 
microarray and real-time qRT-PCR were performed. Significant modifications in miRNA 
expression have been figured out gave us a better look into molecular mechanisms of the anti-
tumour and immuno-modulatory properties of aqueous extract of the medical mushroom P. 
pachyphloeus.  
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II. MATERIALS AND METHODS 
 
II.1. Materials 
 
II.1.1. Mushroom and extract preparation procedure 
 
II.1.1.1. Mushroom and extract preparation procedure 
 
All the samples of Phellinus pachyphloeus (Pat.) Pat. used in this research were collected in 
Vietnam and classified by Prof. Dr. Sc. Trinh Tam Kiet (Centre of Biotechnology, Vietnam 
National University, Hanoi) referring to Larsen & Cobb-Poulle [Larsen & Cobb-Poulle, 
1990]. 
As previously described by Choi and colleagues [Choi et al., 2004], mycelium H1 extracts of 
P. pachyphloeus were prepared by boiling 300 g of 2-cm3 slices of fruiting body in 2 l 
deionized water at 100 °C for 6 hs. Boiling was done three times, and the volume of extract 
was reduced to about 60 ml. The extract was filtered with the Whatman no. 1 filter paper. 
Ethanol (96%) was added in a 3:1 ratio of ethanol and extract, and the mixture was stored for 
18 hs at 4 °C. Precipitated materials were recovered by centrifugation at 50000 ×g for 1 h. 
Precipitants were then resolubilized in 30 ml of distilled water. The sample was lyophilized 
until dry to obtain polysaccharides. Upon determination of the dry weight, the freeze – dried 
extract was reconstituted in cell culture media, RPMI 1640 medium supplemented with 10% 
heat – inactivated fetal bovine serum and 20 µg/ml gentamicin (stock solution: 50 mg/ml), 
was then centrifuged once at 5000 ×g for 1 h. The supernatant was taken, sterilized by 
filtration through a 0.22 µm Millex filter and subsequently stored in the dark at -20 °C for the 
next experiments. 
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II.1.1.2. Metal content analysis of mushroom extract 
 
The freeze-dried extract sample was sent to FOOD GmbH (Jena) and there the content of 
heavy metals in mushroom extract was analyzed, in details, tests for arsenic, lead, cadmium, 
quicksilver, iron, chromium, manganese, nickel, copper, selenium, zinc, and cesium were 
performed. 
 
II.1.2. Cell culture  
 
II.1.2.1. Cell lines 
 
All cell lines were kindly provided by Dr. Hans-Martin Dahse (Department of Infection 
biology, HKI, Jena) 
• HL-60: human acute myeloid leukeamia (DSMZ no.: ACC 3) 
• Hela: human cervix carcinoma (DSMZ no.: ACC 57) 
 
II.1.2.2. Cell culture media 
 
• DMEM with 4.5 g/l Glucose, Pyruvat, GlutaMAXTM-I  
• RPMI 1640 with GlutaMAXTM-I  
Addtion for complete culture medium: 10% FBS; 20 µg/ml gentamicin 
Freezing medium: 70% (v/v) DMEM or RPMI 1640), 20% FBS, 10% DMSO 
 
II.1.3. Chemicals 
 
All chemmicals used were of the highest quality available. 
• RNaseZap® (Ambion) 
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• trypan blue (0.5 % (w/v) in physiological saline) (Biochrom AG) 
• gentamicin sulfate (BioWhittaker) 
• ammonium sulfate, monosodium phosphate - dihydrate (Calbiochem) 
• Tween-20, Nonidet P-40 (NP-40) (Fluka) 
• ECL Plus Western blot detection reagents (GE Healthcare) 
• DMEM, RPMI-1640, gentamicin (Invitrogen) 
• magnesium chloride (Merck) 
• fetal bovine serum (Perbio) 
• CompleteTM Protease-Inhibitor-Cocktail-Tablet (PIC) (Roche Diagnostics) 
• acetone, boric acid, butanol, Coomassie Brilliant Blue G-250, acetic acid, 
Diethylpyrocarbonate (DEPC), ethylene diamine tetraacetic acid (EDTA), ethylene 
glycol tetraacetic acid (EGTA), ethanol, ethidium bromide, glycine, glycerol, 
hydrochloric acid, isopropanol, methanol, milk powder, natrium hydroxide, 
orthophosphoric acid, 2-Propanol, Rotiphorese Gel 30, sodium dodecyl sulfate (SDS), 
Tris-base, sodium azide, sucrose, urea (Roth) 
• ammonium persulfate (APS) (Serva) 
• agarose, bovine serum albumin (BSA), camptothecin, 3-(3-cholamidopropyl) 
dimethylammonio-1-propansulfonate (CHAPS), digitonin, dimethylsulfoxide 
(DMSO), dithiothreitol (DTT), (4-(2-Hydroxyethyl)-1- piperazineethanesulfonic acid 
(HEPES), iodoacetamide (IAA), ß-mercaptoethanol, Orange G, 
phenylmethanesulfonylfluoride (PMSF), tetramethylethylenediamine (TEMED) 
(Sigma-Aldrich) 
 
II.1.4. Solutions 
 
Acrylamide gel solution for SDS-
PAGE (for 4 gels) 
125 ml Rotiphorese Gel 30, 75 ml 1.5 M TrisCl pH 
8.8, 300 mg SDS, 96 ml bidest. water, 3 ml 10 % 
APS, 42 µl TEMED 
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APS 10% (w/v) APS in bidest. water 
Stock solution 100 ml 96% ethanol, 200 ml 88% orthophosphoric 
acid, 350 mg Coomassie Brilliant Blue G-250 
Bradford solution 
Working solution 15 ml 96% ethanol, 30 ml 88% orthophosphoric acid, 
425 ml 
Blocking solution 5% (w/v) milk powder in 1×TBST 
Bromophenol blue solution 1% (w/v) bromophenol blue, 0.6% (w/v) Tris-base in 
bidest. water 
Coomasie staining solution 30% (v/v) methanol, 10% (v/v) acetic acid, 0.25% 
Coomassie Brilliant Blue G-250 in bidest. water 
Coomasie destaining solution 30% (v/v) methanol, 10% (v/v) acetic acid in bidest. 
water 
Displacing solution 0,375 M TrisCl, pH 8.8, 50% (v/v) glycerol, trace 
bromophenol blue in bidest. water 
DTT working solution 1% DTT in SDS equillibration solution 
EDTA 0.5 M EDTA in 1% DEPC-water 
Fixing solution for SDS-PAGE 20% (v/v) methanol, 1.3% (v/v) orthophosphoric acid 
in bidest. water 
IAA working solution 2.5% IAA in SDS equillibration solution 
Lysine 10 mM lysine in bidest. water 
Nonidet NP-40 (0,25%) in distilled 
water 
Nonidet NP-40 (0.25%, v/v) in bidest. water 
50× propidium iodide solution 2 mg/ml propidium iodide in 38 mµ sodium citrate 
pH 7.0 
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Propidium iodide/RNase A solution 40 µg/ml propidium iodide, 250 µg/ml Rnase A in 1× 
PBS 
1 mg/ml proteinase K  1 mg/ml proteinase K in bidest. water 
RNase A solution 100mg/ml RNase A in bidest. water 
SDS equillibration solution 50 mM TrisCl (1.5 M, pH 8.8), 6 M Urea, 30% (v/v) 
Glycerol (87%), 2% (w/v) SDS, trace Bromphenol  
blue in bidest. water 
Sealing solution 0.25 mM Tris-base, 192 mM glycine, 0.1% SDS, 
trace bromophenol blue, 0.5% (w/v) agarose in bidest. 
water 
Sodium azide 0.02% (w/v) sodium azide in bidest. water
 
Sodium hydroxide 50 mM NaOH in bidest. water 
Solution B 1.5 M TrisCl pH 8.9, 0.4% (w/v) SDS, in bidest. 
water 
Solution C 0.5 M TrisCl pH 6.8, 0.4% (w/v) SDS, in bidest. 
water 
Staining solution A 2% (v/v) orthophosphoric acid, 10 % (w/v) 
ammonium sulfate in bidest. water 
Staining solution B 5% (w/v) Coomassie Brilliant Blue G-250 in bidest. 
water 
Staining solution for 2D-DIGE, 2D-
PAGE 
per gel: 200 ml Staining solution A, 5 ml Staining 
solution B, 50 ml methanol 
Stripping solution 62.5 mM TrisCl pH 6.8, 100 mM ß-mercaptoethanol, 
2% SDS in bidest. water 
Tris-Glycine (13 %) resolving gel 6.5 ml Rotiphorese Gel 30, 4.64 ml bidest. water, 3.75 
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solution ml Solution B, 15 µl TEMED, 90 µl 10% APS 
Tris-Glycine (4 %) stacking gel 
solution 
0.65 ml Rotiphorese Gel 30, 3.045 ml bidest. water, 
1.25 ml Solution C, 5 µl TEMED, 25 µl 10% APS 
Washing solution 1 2× SSC 0.2% SDS in DEPC-water 
Washing solution 2 2× SSC in DEPC-water 
Washing 
solution for 
microarray 
Washing solution 3 0.2× SSC in DEPC-water 
Water-saturated butanol 50 ml butanol, 5 ml bidest. water 
 
II.1.5. Buffers  
 
DEPC water 0.2% (v/v) DEPC in bidest. water 
Lysis buffer for 2D-DIGE 4% (w/v) CHAPS, 8 M urea, 10-30 mM TrisCl pH 
8.0- 9.0, 5 mM magnesium acetate, 1 PIC tablet/10 ml 
in bidest. water 
Lysis buffer for 2D-PAGE 9 M urea, 4% (w/v) CHAPS, 40 mM Tris-base, 
1% (65 mM) DTT, 1 PIC tablet/10 ml, 2% (v/v) 
Pharmalyte, 0.002% (w/v) BPB in bidest. water 
10× PBS buffer 1.4 M sodium chloride, 27 mM potassium chloride, 
100 mM disodium hydrogen phosphate, 18 mM 
potassium dihydrogen phosphate in bidest. water 
Phosphate-citrate (PC) buffer 24 parts of 0.2 M disodium hydrogen phosphate and 1 
part of 0.1 M citric acid (pH 7.8) 
4× Protein loading buffer for SDS-
PAGE 
250 mM TrisCl pH 6.8, 8% (w/v) SDS, 20% (v/v) 
glycerol, 0.012% (v/v) BPB, 1.8% (v/v) ß-
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mercaptoethanol in bidest. water 
Stock solution 8 M urea, 4% (w/v) CHAPS 2× Sample buffer 
for 2D-DIGE 
Working solution 2.5 ml sample buffer stock solution, 
% (v/v) Pharmalyte, 2 % (w/v),130 mM DTT 
Rehydration buffer 8 M urea, 0.5% (w/v) CHAPS, 40 mM Tris-base, 
0.2% (w/v) DTT, 0.5% (v/v) Pharmalyte, 0.002% 
(w/v) BPB, in bidest. water 
10× SDS electrophoresis running 
buffer 
250 mM Tris-base, 192 mM glycine, 1% (w/v) SDS 
in bidest. water 
20× SSC 3 M sodium chloride, 0.3 sodium citrate, pH 7.0 in 
bidest. water 
TE buffer 10 mM TrisCl pH 8.0, 1mM EDTA 
20× TBS 400 mM TrisCl pH 7.5, 3 M sodium chloride 
1× TBST 0.1% (v/v) Tween-20 in 1× TBS 
TNN lysis buffer 40 mM TrisCl pH 8.0, 120 mM sodium chloride, 
0.5% NP-40, 1 PIC tablet/10 ml in bidest. water 
Transfer buffer 48 mM Tris-base, 39 mM glycine, 0.0375% (w/v) 
SDS, 20% (v/v) methanol in bidest. water 
 
II.1.6. Markers and protein standards 
 
• Novex® Sharp Protein Standard, BenchMark™ Protein Ladder (Invitrogen) 
• Prestained Protein Marker, Broad Range (New England BioLabs) 
• FastRulerTM DNA ladder (Fermentas) 
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II.1.7. Apparatuses 
 
• Agilent 2100 Bioanalyzer, RNA 6000 Nano LabChip® (Agilent) 
• StepOne real-time PCR system (Applied Biosystems) 
• wash container (Array It) 
• FACSCalibur flow cytometer, Falcon™ polystyrene - cell culter flasks (BECTON 
DICKINSON Biosciences) 
• spectrophotometer DUR640 (Beckmann) 
• Mini-PROTEAN® 3 Cell-System, blot appratus Trans-Blot SD Semi-Dry 
• transfer cell (BioRad) 
• RNase-free pipettor tips (Biozym) 
• 96-microtitrer plate (Brand) 
• heater (Eltret) 
• pipettors, pipettor tips, Eppendorf tubes, centrifuge 5702 R, 5415 C, Speed Vac 3301, 
hybridization block (Eppendorf) 
• 24x 60 LifterSlips™ (Erie Scientific Company) 
• freezer (Forma Scientific Inc.) 
• Amersham HyperfilmTM ECL, CyDye™DIGE Cy™2 minimal dye, CyDye™DIGE 
Cy™3 minimal dye, CyDye™DIGE Cy™5 minimal dye, DALT blank cassette, 
DALT glass plates, DALT separator sheets, Ettan™ IPGphor™ IEF system, EttanTM 
DALTsix electrophoresis vertical system, Ettan™ DALTtwelve gel caster, 
Immobiline™ DryStrip pH 3-11 NL, 24 cm; Immobiline™ DryStrip reswelling tray, 
Pharmalyte 3-11 NL, PlusOne Immobiline™ DryStrip cover fluid, Typhoon Image 
scanner (GE Healthcare) 
• spectrophotometer Spectronix 20 (Genesys Spectronic Instruments) 
• water bath (GFL) 
• micro test plate (Greiner Bio-One) 
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• cell culture incubator BB 6060, Laminar-Box LaminAir® HB2472 (Heraeus 
Instruments) 
• shaking machine KS250 basic, thermomixer (Ika- Labortechnik) 
• film X-OMATTMAR, XAR 5 (Kodak) 
• centrifuge tubes (LabCon) 
• Immobilon Transfer membrane filter type PVDF (Millipore) 
• GenePix® 4000B microarray scanner (Molecular Devices) 
• cryo 1°C freezing container, NYL FilterUnit (Nalgene) 
• NanoDrop® 100R (Nanodrop technologies) 
• spectrophotometer 1420 Multilabel Counter Victor 3V (Pelkin Elmer) 
• Neubauer-improved counting chamber, cuvettes, gloves, Rotilabo® syringe filter 
sterile (0.22 µm), pipettor tips (Roth) 
• balance Talent TE1502S, Expert LE1003S-OCE (Sartorius) 
• slab gel dryer (Savant Intruments) 
• electronic cell analyser system CASY 1 (SCHÄRFE) 
• vortexer VF2, ultrasonic apparatus Labsonic U (Schütt Labortechnik) 
• microwave (Siemens) 
• centrifuge Sigma 4K15 (Sigma) 
• GelVue UV-transilluminator (Syngene) 
• SUNRISE micro plate reader (TECAN) 
• concentrator SC210A Speed Vac™ Plus (Thermo Savant) 
• serological pipettes (5, 10, 25 ml ) (TPP) 
• autoclave Type 500 (Varioklav) 
• light microscope Axionvert25 (Zeiss) 
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II.1.8. Kits, commercial solutions and commercial master mixes 
 
• MirVana™ miRNA Isolations Kit (Ambion) 
• RNA 6000 Nano Assay Kit (Agilent) 
• TaqMan® microRNA assay, TaqMan® microRNA Reverse Transcription Kit, 
Taqman®  Universal PCR Master Mix, No AmpErase® UNG(Applied Biosystems) 
• Quant-iT ™ RiboGreen® RNA Assay Kit, NCode™ miRNA Labeling System, 
NCode™ Multi-Spezies miRNA Microarray V2, PureLink™ miRNA Isolations kit 
(Invitrogen) 
• CASYTON (SCHÄRFE) 
 
II.1.9. Antibodies 
 
• sheep anti-mouse IgG, peroxidase-conjugate (whole antibody) [NXA931] 
(Amersham) 
• monoclonal mouse anti-Caspase-8 (Ab-3) IgG [AM46] (Calbiochem) 
• polyclonal rabbit anti-Caspase-6 IgG [9762], polyclonal rabbit anti-cleaved Caspase-6 
(Asp162) IgG [9761], polyclonal rabbit anti-Caspase-7 IgG [9492], polyclonal rabbit 
anti-Caspase-3 IgG [9662], polyclonal rabbit anti-cytochrom c IgG [4272], polyclonal 
rabbit anti-Caspase-9 IgG (Cell Signalling Technology) 
• AffiniPure goat anti-rabbit IgG 
• (H+L) peroxidase-conjugate [111-035-003] (Jackson Immunoresearch Laboratories 
Inc.) 
• monoclonal mouse anti-actin (C-2) IgG [sc-8432], polyclonal rabbit anti-Ly-GDI 
(Santa Cruz) 
• monoclonal mouse anti-ß-actin (AC-74) IgG [A 5316] (Sigma) 
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II.1.10. Software 
 
• Agilent 2100 Expert Software (Agilent) 
• CellQuest (Becton Dickinson) 
• Labscan, DeCyder™ Differential Analysis Software, ImageQuant (GE Healthcare) 
• GenePix® Pro 4.0 and 6.0 (Molecular devices) 
• CASYSTAT (SCHÄRFE) 
• Magellan (TECAN) 
 
II.2. Methods 
 
II.2.1. Cell culture 
 
The cells were maintained in DMEM or RPMI 1640 supplemented with 10% heat – 
inactivated fetal bovine serum and 20 µg/ml gentamicin and grown in an incubator at 37 °C 
with 5% CO2. All experiments were performed on exponentially growing cell cultures. The 
doubling time of HL-60, at densities of 1-3 × 105 cells/ml, was 24-25h. All experiments were 
repeated at least once with essentially identical results. 
Before treatment, cells were seeded at concentration 1 × 105 cells/ml in cell culture flask and 
incubated over night. In the next day, cell number was checked again by counting with 
haemocytometer. When reaching the concentration 2 × 105 cells/ml, the cells were cultured in 
the presence or absence of variable concentrations of mycelium H1 extract. 
 
II.2.2. Antiproliferative and cytotoxic assay [Dahse et al., 2001] 
 
Approximately 1 × 105 cells were seeded with 0.1 ml RPMI 1640, containing 25 µg/ml 
gentamicin sulphate, but without HEPES, per well of the 96-well micro plate. Cells were then 
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incubated for 72 hours at 37°C in a humidified atmosphere and 5% CO2 with or without the 
extract. 
Suspension cultures of HL-60 in micro plates were analysed by an electronic cell analyser 
system CASY 1 with the software CASYSTAT for data evaluation. In detailed, the 0.2 ml 
content of each well in the micro plate was diluted 1:50 with CASYTON. Every count/ml was 
automatically calculated from the arithmetic mean of three successive counts of 0.4 ml each. 
From the dose response curves the GI50 values were calculated with CASYSTAT. The GI50 
value was defined as being where the concentration-response curve intersected the 50% line, 
determined by means of the cell counts/ml, compared to control. The essential parameters for 
the estimation of growth inhibition and for changes in diameter distribution curves are 
expressed as diagrams. 
The other cells were fixed by glutaraldehyde and stained with a 0.05% solution of methylene 
blue for 15 min. After gently washing the stain was eluted by 0.2 ml of 0.33 N HCl in the 
wells. The optical densities were measured at 660 nm in SUNRISE micro plate reader. 
Comparisons of the different values were performed with software Magellan. 
 
II.2.3. Apoptotic detection methods 
 
II.2.3.1. Camptothecin-induced apoptosis as control  
 
As control for all apoptotic detection methods, apoptosis was induced in HL-60 cells by 
adding camptothecin with the end-concentration 5 µM into the culture medium. 
 
II.2.3.2. DNA fragmentation analysis [Gong et al., 1994] 
 
About 2 × 106 cells untreated or treated cells were collected by centrifugation at 80g for 4 
min, washed once in 10 ml cold PBS. The cell pellet was carefully resuspended in 1 ml PBS 
and then while vortexing, 10 ml of ice cold 70% ethanol was put drop by drop into tubes 
containing the cell suspension. The cells were stored in the fixative at –20 °C generally for 
24-72 hs. The cells were then centrifuged at 800 ×g for 5 min and the ethanol was thoroughly 
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removed. The cell pellets (1-2 × 106 cells), were resuspend in 40 µl of phosphate-citrate (PC) 
buffer, at room temperature, for at least 30 min. After centrifugation at 1000 ×g for 5 min, the 
supernatant was transferred to new tubes and concentrated by vacuum in a SpeedVac 
concentrator for 15 min. A 5-µl aliquot of 0.25% Nonidet NP-40 was then added followed by 
5 µl of a solution of 1mg/ml RNase A. After 30 – 60 min incubation at 37 °C in a 
thermomixer, 5 µl of a solution of 1 mg/ml proteinase K was added and the extract was 
incubated for an additional 30 – 60 min at 37 °C in the thermomixer. After the incubation, 
DNA concentration and pureness were measured by Nanodrop. If another DNA purification 
step was necessary, 2 volume ice cold 96% ethanol and 0.1 volume 3M sodium acetate were 
added and the tube was incubated in an ethanol bad at –20 °C for 2 hs for DNA precipitation, 
then centrifuged, the pellet was dried with Speed Vac concentrator and 15 µl TE-buffer was 
added and DNA concentration and pureness are measured again by Nanodrop. 2 µl of 6× 
loading buffer was added and the entire content of the tube was transferred to the gel. 
Horizontal 1% agarose gel electrophoresis was performed at 5 V/cm until the bromophenol 
blue front runs through two third of the gel. Because ethidium bromide was added before into 
the gel solution while casting, DNA in the gels was visualized under UV light. 
 
II.2.3.3. DNA content analysis by flow cytometry [Gong et al., 1994] 
 
Pellets of cells removed from the PC buffer described above were washed once with PBS and 
then resuspended with fresh PI/RNase A solution. The cells were incubated for 30 min in the 
dark at room temperature. Each sample was transferred from a microfuge tube to a FACS 
tube, mix by syringes. The red fluorescence of individual nuclei was measured with a 
FACSCalibur flow cytometer. 10 × 103 events were collected for each sample, and the data 
were acquired and analyzed using CELLQUEST software. The cell cycle distribution 
(including the percentage of apoptotic cell) was also analyzed. 
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II.2.4. Analysis of protein expression 
 
II.2.4.1. Protein extraction 
 
II.2.4.1.1. Protein extraction for SDS – polyacrylamide gel electrophoresis 
 
Untreated or treated cells were collected by centrifugation at 80 ×g for 4 min, washed twice 
with cold PBS and immediately the NP-40 lysis buffer was added and incubated for 30 min. 
The cell lysate was sonicated 3 times on ice, 0.5 s impulse, 50% power level, 10 s interval and 
then centrifuged at 16000 ×g for 30 min. The supernatant was taken as protein extract. 
 
II.2.4.1.2. Protein extraction for two-dimensional gel electrophoresis 
 
After 30 h incubation with or without mycelium extract of P. pachyphloeus, HL-60 cells were 
collected by centrifugation at 80 ×g for 4 min, washed twice with cold PBS. 500 µl cold lysis 
buffer was added and incubated for 30 min at room temperature. The cell lysate was sonicated 
3 times on ice, 0.5 s impulse, 50% power level, 10 s interval and then centrifuged at 16000 ×g 
for 30 min. The supernatant was taken as protein extract. 
 
II.2.4.2 Protein quantification (Bradford assay) 
 
The spectrophotometer was warmed up 15 min before use. Seven standard solutions 
containing 0, 1, 2, 5, 10, 20, 25 µg/ml BSA were prepared and filled to 100 µl in 1.5 ml 
Eppendorf tubes. 100 µl sample containing around 1 – 20 µg protein was prepared. 900 µl of 
dye reagent was added to the tubes containing standard solutions and protein samples, gently 
mixed and incubated for 5 min at room temperature. The mixtures were transferred into 
cuvettes and the absorbance at 595 nm of the spectra of the standard solutions and protein 
samples were examined. A graph of absorbance at 595 nm versus protein concentration for 
the protein standards was prepared. The Bradford assay gives a hyperbolic plot for absorbance 
versus protein concentration but within a range of relatively low protein concentrations, the 
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hyperbolic standard curve can be approximated reasonably well by a straight line. To 
determine the protein concentration of a sample from it absorbance, use the standard curve to 
find the concentration of standard that would have the same absorbance as the sample. 
 
II.2.4.3. Immunoblot analysis of proteins 
 
II.2.4.3.1. One-dimensional SDS – Polyacrylamide gel electrophoresis of proteins  
 
Aliquots containing 30 – 80 µg of protein samples were mixed with loading buffer and the 
mixtures were heated to 95 °C for 5 min for denaturation, chilled on ice, short centrifuged and 
subjected to one – dimensional electrophoresis (1-D PAGE) in 12% gel in SDS. For prerun, a 
voltage of 0.8 – 1 mA/cm2 was applied to the gel. After the dye front moved into the resolving 
gel, the voltage was increased to 1.5 – 2 mA/cm2 until the bromophenol blue front reached the 
bottom of the resolving gel. Proteins in gel could be stained with Coomassie brilliant blue or 
used to establish an immunoblot. For staining with Coomassie, the gel was soaked at first for 
30 min in Coomassie staining solution and then in Coomassie destaining solution until the 
protein bands became obviously clear. 
 
II.2.4.3.2. Immunoblot analysis 
 
After separated by SDS – polyacrylamide gel electrophoresis, proteins were transferred to a 
pre-wetted nitrocellulose or a PVDF membrane at 23 V for 1 h. In the case of nitrocellulose 
membrane, the membrane was pre-wetted by soaking in transferring buffer for at least 15 min. 
In the case of PVDF membrane, the membrane was pre-wetted by soaking in methanol for 1 
min and then in transferring buffer for at least 15 min.  
After blotting, the membranes were blocked with 5% nonfat milk in TBST (blocking solution) 
for 1 h at room temperature or over night at 4 °C. Membranes were washed several times with 
TBST buffer and incubated for 3 hs with the primary antibody (diluted to 1:500 to 1:2000 
diluted in blocking solution) at room temperature. After several wash with TBST buffer, the 
membranes were incubated with horseradish peroxidase – conjugated secondary antibodies 
for 1 h at room temperature (diluted to 1:1000 to 1:2000 in blocking solution).  The 
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membranes were washed with TBST buffer several times. The antigens were then detected 
using the enhanced chemiluminescence Western blotting detection system ECL Plus 
according to the manufacturer instruction and visualized by autoradiography on X – ray film. 
 
II.2.4.3.3. Stripping 
 
For detection of different proteins on a membrane, antibodies after the first handling could be 
removed. The membrane was soaked and shaken in 55 °C – pre-warmed stripping solution for 
30 min. After that, the membrane was intensively washed with TBST several times. For the 
second time detecting with antibodies, the membrane must be blocked again. 
 
II.2.4.4. Two-dimensional Gel Electrophoresis (2D-GE) 
 
II.2.4.4.1. Conventional two-dimensional gel electrophoresis (2D-PAGE) 
 
Rehydration and strip loading 
 
The immobilized pH gradient (IPG) gel strips with a non-linear separation range of pH 3-11 
(24cm) were rehydrated overnight at room temperature in the Immobiline DryStrip 
Reswelling Tray. 1 mg of total protein lysate in a total volume of 450 µl of the rehydration 
solution was applied to the reservoir slots of the Reswelling Tray, and then the IPG strips 
were soaked individually. Strips were prevented from dehydration and oxidation by covering 
with mineral oil. 
 
Isoelectric Focusing 
 
The rehydrated IPG strips were placed in the Ettan IPGphor Manifold. Thereafter, the proteins 
were separated according to their pI. The isoellectric focusing was carried out at 20 °C with 
the IPGphor system, covered with mineral oil. 
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Homogeneous SDS Gel casting 
 
Laboratory-made gels were casted in glass cassettes using Ettan DALTtwelfeTM system caster. 
The inner-side of the glass plates was carefully cleaned to remove any dust. The cassettes 
alternating with separator sheets were assembled into the caster, the offset edges of the 
cassettes up. Each 75 ml gel solution was prepared per 1-mm glass cassette. At first the 
hydrostatic balance chamber was filled with 100 ml of the displacing solution. 
 
Equilibration / S-S bond reduction and alkylation 
 
Prior to separation in the second dimension, the IEF gels (IPGs) were equilibrated in 
equilibration solution, first for 30 min with an addition of 65 mM DTT (reduction step), and 
finally for 15 min with  135 mM IAA (alkylation step). Excess of equilibration solution was 
removed by briefly dipping the IEF gels into deionized water. 
 
SDS Electrophoresis /Second dimension (SDS-PAGE) 
 
A separation according mainly to the molecular mass was obtained after denaturation of the 
protein by SDS, an anionic detergent, giving the proteins a negative charge and a similar 
shape by removing the secondary structure. 
The casting cassettes (containing the polymerized gels) were shortly washed with deionized 
water to remove gel pieces. Thereafter, the IPG strips were placed, acidic end on the left, 
directly onto the acrylamide gel surface and remaining air bubbles between both gels were 
removed with a spatula. Strips were covered to be free of air bubble with 60 °C – heated 
agarose – sealing solution.When agarose was gelatinized, the gel cells were inserted into the 
Ettan DALTsix filled with 1× electrophoresis buffer. Finally, the 2D gels were overlaid with 
2× electrophoresis buffer. Electrophoresis of the SDS-polyacrylamide gels were performed at 
20 °C using a two-step increase of current until the bromophenol blue dye reached the bottom 
of the glass plates. 
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II.2.4.4.2. Fluorescence difference gel electrophoresis 
 
CyDye DIGE Fluor minimal dyes (Cy2, Cy3, Cy5) were reconstituted in 99.8% anhydrous 
dimethylformamide (DMF) giving a concentration of 1 mM and stored at –20 °C. Routinely 
50 µg protein was labelled in each reaction. 1/3 of each of the untreated and treated samples 
were mixed together to create an internal standard sample and then labelled with Cy2. The 
remaining 2/3 of the untreated sample was labelled with Cy3 and the remaining 2/3 of the 
treated sample was labelled with Cy5. 
The differently labelled protein samples and the unlabeled protein from untreated and treated 
samples (each 425 µg) were combined into a single microfuge tube and mixed. 225 µl of 2× 
sample buffer and rehydration buffer were added to have total volume 450 µl and then the 
mixture was pipetted directly into the slot of the Immobiline dry strips reswelling tray for 
rehydration. All labelling reactions were performed in the dark to avoid the exposure of 
CyDyes to light. 
Rehydration, first dimension IEF and second dimension SDS-PAGE were carried out in the 
same way as in the conventional 2D-PAGE experiment but the exposure of proteins labelled 
with CyDyes, the strips when running the first dimension and the gels when running second 
dimension to all light sources were kept to a minimum.  
2D-gels of CyDye-labelled samples were scanned with the Typhoon variable mode imager 
9400. Scan parameters were set followed the protocol from manufacturer. DIGE images were 
cropped using ImageQuant TL software and then analyzed using DeCyder 2D software 
version 6.5. The protein spots were detected and quantified by DIA (Differential In-gel 
Analysis) module on a set of images, from the same gel. After the detection, the DIA files 
were imported and analyzed by BVA (Biological Variation Analysis) module. Multiple 
images from different gels were matched to get statistical data with the p-value from the 
Student’s t-Test from different protein abundance levels between untreated and treated 
samples. 
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II.2.4.4.3. Fixation, Staining and destaining 
 
The gels were fixed for 1 h with fixing solution, stained with colloidal blue G-250 for 24 – 36 
hs, and then destained with water to decrease background. Gels were scanned (300 dpi 
resolution) with Image Scanner UMAX and Magic Scan software. 
 
II.2.4.4.4. Spot picking and digestion 
 
A transferring plan for gel piece arrangement in micro plates was prepared. Finally, the 
protein spots shown to be different between untreated and treated samples were carefully 
excised out of the gels by using pipette tips cut with the tube cutter (position 3) with caution 
to avoid keratin contaminations and stored at –20 °C until mass spectrometry analysis.  
 
II.2.4.4.5. In-gel digestion 
 
Destaining, digestion and peptide extraction were done completely automaticcally on Ettan 
digester. The standard program included 4 washing steps with 70 µl 50 mM 
ammoniumbicarbonate in 50% acetonitrile (ACN), 3 washing steps with 70 µl 70% ACN 
(time each step: 20 min) and the peptide transfer with 2 times addition and transfer of 25 µl 
0.1% TFA in 50% ACN. After dehydration with ACN, the proteins were digested in gel with 
8 µl of 6.25 ng/µl of porcine trypsin buffered with 50 mM ammoniumbicarbonate (freshly 
diluted) at 37 °C for 22 – 24 hs. The generated peptides were extracted. The peptide extracts 
were used for MALDI-TOF-MS analysis 
 
II.2.4.4.6. MALDI measurement 
 
Matrix assisted laser desorption/ionization-time of flight-mass spectrometry (MALDI-TOF-
MS) measurements were carried out on MALDI micro MX. 1 µl of the peptide extracts were 
manually spotted on a polished steel target plate and co-cristallized in 1 µl α-cyano-4-
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hydroxycinnamic acid matrix for the MALDI-TOF-MS analysis. For lock mass human [glu] - 
fibrinopeptide b was used. An internal calibration using 2 BSA sample spots on the Waters 96 
formate low mass sample plate was performed. 
 
II.2.5. Analysis of miRNA expression 
 
II.2.5.1. Total RNA isolation procedure 
 
Total RNA was isolated using mirVana miRNA isolation kit following the protocol of the 
manufacturer. Briefly, untreated or treated cells were collected by centrifugation, washed 
twice with cold PBS and then lysed in a denaturing lysis solution which stabilized RNA and 
inactivated Rnases. The lysate was then extracted once with acid-phenol: chloroform which 
removes most of the other cellular components, leaving a semi-pure RNA sample. This was 
further purified over a glass-fibre filter with solutions that specifically formulated for miRNA 
retention to avoid the loss of small RNAs to yield total RNA. 
 
II.2.5.2. RNA quantification and quality assessment  
 
RNA concentration and pureness were roughly estimated by measuring with Nanodrop. Then 
total RNA was analyzed by using Agilent RNA kits with the Agilent 2100 bioanalyzer. RNA 
concentration and integrity were determined at least in duplicate. 
 
II.2.5.3. Microarray 
 
II.2.5.3.1. miRNA labelling and hybridization [Landers, 2007] 
 
microRNA-enriched samples were prepared using PureLinkTM miRNA isolation kit 
(Invitrogen) and then enzymatically labelled with the Ncode miRNA Labelling System. 
Labelled miRNAs were then hybridized to Ncode Multi-Species miRNA microarray slides. 
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II.2.5.3.2. Image analysis and data processing 
 
Microarray data was obtained using the Axon GenePix 4000B scanner and associated 
GenePix Pro 6.0 software. Each of the data sets used was filtered using signal-to-noise 
criteria. Quality data was defined to have signal-to-noise ratio more than 3 in both channels.  
The data were then exported to GenePix Results GPR Files and converted using Express 
Converter Version 1.7 (Institute for Genomic Research, USA). The Microarray Data Analysis 
System (MIDAS) version 2.19 (Institute for Genomic Research, USA) program [Saeed, 2003] 
was used to normalise raw experimental array data. In brief, three types of normalisation were 
performed. Firstly, total intensity normalisation was performed, followed by Lowess 
normalisation and finally, in-slide replicate normalisation [Quackerbush, 2002]. 
The Multi-experimental Viewer (MeV) Version 4.1 (Institute of Genomic Research, USA) 
program was used to identify genes and expression patterns of interest. 
 
II.2.5.4. miRNA qRT-PCR [Chen et al., 2005] 
 
Expression of hsa-miR-338, hsa-miR-378 were verified by quantitative real-time PCR. 
Purified RNA was reverse transcribed and then PCR-amplified using TaqMan microRNA 
assays in StepOne real-time PCR system. Amplification of the U6 snRNA transcript was 
performed in every sample and the expression of each miRNA relative to U6 RNA was 
determined using the 2– CT method [Livak & Schmittgen, 2001]. Experiments for both 
miRNAs were done with 3 differently biological samples, each sample in triplicates. 
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III. RESULTS 
 
In the present study, we report the first time some investigations about molecular mechanisms 
responsible for the anti-tumour property in human leukeamia cell line HL-60 upon treatment 
with water-soluble extract of medical mushroom Phellinus pachyphloeus. 
 
III.1. Metal content of H1 mushroom extract 
 
Many mushroom species are able to accumulate relatively high concentrations of metals of 
which many are toxic and can be harmful for human health, including arsenic, lead, cadmium, 
mercury as well as cesium. It is well known that a wide variety of metals, depending on cell 
type, exposure concentrations and time, act as mutagenic and carcinogenic agents or might 
trigger apoptosis [Pulido & Parrish, 2003]. Therefore, before validating any anti-tumour 
properties, it is necessary to determine whether the metal content of the promising mushroom 
is above allowable limit or not. 
In Table 2 we present elemental concentrations (µg.g-1, dry weight) of our mushroom extract 
after lyophilized and molar concentrations (nM) of the same extract after resuspended in 
culture medium. 
When studying the apoptosis induction mechanism in adult rat hepatic stem cells by arsenic 
trioxide and lead acetate, Agarwal and colleagues treated cells with As and Pb at 40µM 
concentration upon 6h [Agarwal et al., 2008]. Their treatment resulted in 20% death of the 
isolated oval cells and the activation of caspase-3, caspase-9 and the dephosphorylation of 
survival factors like p38 and Erk play essential roles in the induction of apoptosis. It has 
previously been shown that the low concentration 0.5 µM arsenic trioxide As2O3 failed to 
induce caspase activation. In HL-60, it has been shown that caspase-9 activation observed in 
response to 4.0 µM As2O3 upon 48 h treatment and signalling through mitochondria pathway 
is the major route for As2O3-induced apoptosis [Jiang et al., 2008]. Therefore it was obvious 
that arsenic is present in our mushroom extract at a non-toxic level. Lead could also not be the 
apoptosis-caused factor. 
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Previous study demonstrated that treatment of HL-60 cell with 12.5 µM concentrations of Cr 
and Cd ions for 48 h produced significant induction of the apoptotic cell population and 
resulted in the increase in cytochrome c reduction [Baqchi et al., 2000]. In this study, 
concentrations of Cd and Cr in the extract used to treat HL-60 cells were less than potential 
concentrations for apoptosis. These results suggested that these two cations exhibited no 
dramatic effects on HL-60 cells. 
 
Concentration Concentration in Apoptosis-inducing 
concentration (nM) Metal (µg.g-1, dry 
weight) 
culture medium 
containing mushroom 
extract (nM) In HL-60 In other cell lines 
References 
As 1,2 16,017 4000 Rat hepatic stem 
cell: 40000 
[Jiang et al., 2008; 
Agarwal et al., 
2008] 
Pb 0,17 0,820  Rat hepatic stem 
cell: 40000 
[Agarwal et al., 
2008] 
Cd 0,08 0,712 12500  [Baqchi et al., 
2000] 
Hg 0,053 0,264 30000  [Araragi et al., 
2003] 
Fe 108 1933,924    
Cr 1,1 21,155 12500  [Baqchi et al., 
2000] 
Mn 270 4914,627  U87 (one of the 
most sensitive): 
1000000 
[Puli et al., 2006] 
Ni 1,9 32,372  T cell hybroma: 
80000 
[Kim et al., 2002] 
Cu 37 582,255 250000  [Ma et al., 1998] 
Se 0,19 2,406 20000  [Kim et al., 2001] 
Zn 12 183,514 25000  [Kondoh et al., 
2005] 
Cs 3,6 26,277    
 
Table 2: Concentrations of heavy metals in H1 mushroom extract (µg.g-1, dry weight) and 
concentrations of extract (which was resuspended in culture medium) used to treat cells (nM). Apoptosis-
inducing concentration (nM) in HL-60 and other cell lines currently reported on the scientific literature were 
shown for comparison. 
 
It is well known long ago that mercurial compounds induce apoptosis in immune system cell 
[Pollard & Hultman, 1997]. Araragi and colleagues reported the induction of apoptosis via 
mitochondrial pathway upon treatment with 30 µM mercuric chloride HgCl2 at 9 h [Araragi et 
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al., 2003]. Our finding indicated that it is impossible that the amount of Hg in our extract 
could cause apoptosis in HL-60 cells. 
Although being an essential trace metal, manganese (Mn) intake in excess results in toxicity 
and CNS is among one of the most sensitive tissues. As previously demonstrated, human 
glioblastoma U87 cells underwent apoptosis upon treatment 1mM Mn after 72h [Puli et al., 
2006]. In our observation, Mn content was about 200 times and treatment time was two times 
less compared to the above study and leukaemia cells are not so sensitive to Mn as CNS cells 
therefore in our extract, Mn was still at the harmless level.  
As previously reported, apoptosis is induced via activation of caspase in HL-60 cells treated 
with zinc (Zn) at 25 µM [Kondoh et al., 2005]. Various forms of selenium compounds have 
been also reported to be potent inducers of apoptosis and exert a cytotoxic effect in a dose-
dependent manner in HL-60 cells [Kim et al., 2001]. Both treatments with 50 µM Se-
methylselenocysteine (MSC) and with 20 µM selenite induced apoptosis in HL-60 cells and 
selenite did not show the full range of apoptotic features. Nickel acetate treatment at the 
concentration 80 µM rapidly induces apoptosis in T cell hybridoma cells through an increase 
in FasL protein levels and transient activation of caspase-3 [Kim et al., 2002]. Ma et al. found 
that cupric nitrilotriacetate (Cu-NTA), which was added to HL-60 cells to give a final 
concentration of copper of 250 µM, induced oxidative DNA damage and apoptosis [Ma et al., 
1998]. Comparing with the elemental amounts of Zn, Se, Ni and Cu in our extract (see Table 
2); we demonstrate that contents of Zn, Se, Ni and Cu play no role in the cellular apoptosis 
induced by our mushroom extract. 
 
III.2. H1 Mushroom extract treatment of HL-60 cells 
 
In a first set of experiments, HL-60 cells were incubated with different concentrations of 
mushroom extract for different periods of time. Untreated HL-60 cells were used as control. 
The range of tested concentrations was 0.5 mg/ml to 2 mg/ml and time incubation was 12 hs, 
24 hs, 36 hs and 48 hs. It turned out that 1 mg/ml mushroom extract efficiently induced 
apoptosis after 36 hs of treatment and this concentration and time point were therefore used as 
standard condition. 
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III.3. Anti-proliferative effects of H1 mushroom extract 
 
The activities of mushroom extracts were evaluated in various bioassay test systems including 
cytotoxic (Hela cells) and anti-proliferative assays (HL-60 cells). Cells were incubated in the 
presence or absence of H1 mushroom extract. 
Cytotoxicity assay was performed in human cervical (Hela) cell line. As shown in Figure 6, 
populations of treated cells and cells left untreated diverged from one another. In detail, H1 
extract up to the concentration of 1 mg/ml did not exhibit any detectable cytotoxicity towards 
Hela. Percentage of treated cells was about 35 % after 72 hs of treatment with 1 mg/ml 
mushroom extract. 
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              Figure 6: Dose response curve of Hela cells after 72h-treatment with H1 mushroom extract 
 
Incubation of human acute myeloid leukeamia HL-60 led to a dose-dependent inhibition of 
cell proliferation. GI50 values (the concentration that inhibits cell growth by 50%) obtained 
after 36 h of treatment was 0.84 ± 0.064 mg/ml (Figure 7). Effectiveness of H1 extract 
increased with elongated treatment times. Collectively, our mushroom extract has no 
cytotoxic effect and shows anti-proliferative effect at high concentrations. For the next 
experiments, HL-60 was only treated with extract at concentration: 0.5 mg/ml, 1.0 mg/ml and 
1.5 mg/ml. 
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              Figure 7: Dose response curve of HL-60 cells after 36h-treatment with H1mushroom extract. The 
viability percentage of HL-60 cells treated for 36h with different concentrations H1 mushroom extract as 
estimated by the assay. The results were represented as the percentage of the number of treated cells versus the 
number of control untreated cells. 
 
III.4. Cell cycle regulation 
 
To get first hints about the mechanisms responsible for the anti-tumour effect of P. 
pachyphloeus extract, we focused initially our study on how the effect of H1 extract on cell 
cycle regulation would be related to the observed anti-proliferative activity. To distinguish 
between necrotic and apoptotic cell death, a cell cycle analysis was performed. Cell cycle 
distribution was assessed by flow cytometry after staining fixed cells with propidium iodide 
and thereby cells in different phases of cell cycle were discriminated: G1, S, G2/M and 
hypodiploid cells. Because apoptosis leads to DNA strand breaks due to the activation of 
DNA digesting enzymes, this method can be used to determine the number and percentage of 
apoptotic cells in a cell population.  
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A.                                                                      B. 
  
C.                                                                       D. 
 
E.                                                                         
  
Figure 8: Cell cycle distribution of HL-
60 after exposure to H1 mushroom 
extract for 36h. Cytometric analyses were 
performed using PI staining. A highly 
significant increase of cells in sub-G1 
phase as well as a decrease of those in G1 
and G2/M phases is shown.  
 
sub-G1 
G1 
S
 
G2/M 
 III. RESULTS 
  
 
 
48 
Figure 8 illustrated the DNA content which indicated the different distributions of phases of 
cell cycle in treated and control cells. The control group showed a prominent G1 phase 
whereas; 1.0 mg/ml and 1.5 mg/ml of mushroom extract significantly reduced the portion of 
cells in G1-phase and simultaneously decreased the percentage of cells in S/G2M-phase over a 
period of 36 hours.  
The reduced DNA content of apoptotic nuclei resulted in an unequivocal hypodiploid DNA 
(sub-G1) peak which was easily discriminable from the narrow peak of cells with normal 
(diploid) DNA content. Untreated cells exhibited a minimal amount of cells in sub-G1 phase 
consistent with the low background level of apoptosis. However, upon treatment with H1 
extract, cells exhibited a significantly greater amount of cells in sub-G1 compared to control 
cells. The presence of a distinct sub-G1 peak was depicted in Figure 9. The percentage of 
apoptotic nuclei was quantified and shown in this figure. After 36 hs the percentage of cells in 
sub-G1 increased from 12.84 % in untreated cells to 37.81% and 63.41% with increasing 
concentrations from 1.0 to 1.5 mg/ml of mushroom extract, respectively. This result indicated 
that the mushroom extract induces apoptosis.  
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Figure 9: Histogram of cell cycle arrest and cell apoptosis. Histogram showed the percentages of 
cells at various phases of cell cycle of HL-60 cells with and without mushroom extract treatment: sub-G1 phase 
(black bar), G1 phase (dark gray bar), S phase (light gray bar) and G2/M phase (white bar). 
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III.5. DNA fragmentation analysis 
 
The cleavage of DNA between nucleosomes by endonucleases produced fragments in 
multiples of approximately 180 bp. DNA fragmentation can be visualized by agarose gel 
electrophoresis, thereby a typical DNA-ladder pattern formed by separation of DNA 
fragments can be observed. Since several compounds leading to cell cycle progression 
subsequently induce DNA fragmentation and apoptosis, the DNA integrity was examined 
after exposing HL-60 cells to H1 extract at increasing concentrations 0.5 mg/ml, 1.0 mg/ml, 
and 1.5 mg/ml for 36 hours and results were depicted in Figure 10. An enhanced DNA 
fragmentation in to mono- and oligonucleosomes, a typical hallmark of late apoptosis, was 
obvious at the concentrations 1.0 and 1.5 mg/ml. Therefore it was firmly established that the 
anti-proliferative effect of H1 mushroom extract was mediated by activation of the apoptosis 
pathways. 
 
                                         
Figure 10: Representative results of a qualitative analysis of fragmented DNA 
separated on agarose gels. Lane 1: DNA marker; lane 2: negative control; lanes 3: cells 
exposed to 5 µM Camptothecin; lane 4-6: cells incubated with increasing concentrations of 
H1 mushroom extract. 
MK C CPT 0,5 1,0 1,5 
   H1 mushroom 
  extract (mg/ml) 
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III.5. Cleavage and activation of caspases in H1 mushroom extract-
treated cells 
 
It is well known that a family of cysteinyl proteases, the so-called caspases, is involved in 
apoptotic cell death. Caspases are synthesized as inactive zymogen and converted to an active 
complex composed of several heterodimeric subunits. To confirm the apoptosis-inducing 
potential of H1 extract, we analyzed cleavage and activation of caspases. The processing of 
procaspases was monitored in immunoblot analyses using antibodies which are specific to 
individual proteases. 
 
 
Figure 11: H1 mushroom extract induces activation of caspase-3. HL-60 cells were incubated with 
the indicated concentrations of mushroom extract for 12 hs, 24 hs, 36 hs and 48 hs. Western blot analysis 
showed the activation of caspase-3 resulting in time-dependent and concentration dependent appearance of the 
p17 subunit. After being exposed, the membrane was stripped and blotted with anti-Actin antibody as a loading 
control.  
 
Treatment of HL-60 cells with H1 mushroom extract resulted in the conversion of the inactive 
32-kDa caspase-3 precursor to the proteolytically cleaved p17 subunit, indicating that 
1.0 1.5 0.5 0 1.0 1.5 0.5 0 H1 mushroom extract (mg/ml) 
24h 12h 
pro-caspase 3 
cleaved caspase 3 
1.0 1.5 0.5 0 1.0 1.5 0.5 0 H1 mushroom extract (mg/ml) 
48h 36h 
actin 
pro-caspase 3 
cleaved caspase 3 
actin 
17 kDa -- 
32 kDa -- 
17 kDa -- 
    32 kDa -- 
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caspase-3 was activated during mushroom extract-induced apoptosis. In detail, H1 extract did 
not affect the expression of pro-caspase-3 protein however the active form of caspase-3 (p17 
subunit) was concentration-dependently increased by mushroom treatment, as shown in 
Figure 11. After 24 h of treatment, H1 extract at a concentration of 1 mg/ml, as well as 1.5 
mg/ml induced caspase-3 cleavage. After 36 h, caspase-3 cleavage was markedly induced by 
H1 extract. These results show that our mushroom extract at the 1mg/ml concentration 
induces apoptosis rather than necrosis.  
 
 
 
Figure 12: H1 mushroom extract induces activation of caspase-6. HL-60 cells were incubated with 
the indicated concentrations of mushroom extract for 12 hs, 24 hs, 36 hs and 48 hs. Western blot analysis 
showed the activation of caspase-6 resulting in time-dependent and concentration-dependent appearance of the 
p18 subunit. After being exposed, the membrane was stripped and blotted with anti-Actin antibody as a loading 
control. 
 
H1 mushroom extract was also able to induce a highly significant increase of caspase-6 and 
caspase-7 activities. Figure 12 showed that the p18 subunit of the active caspase-6 was 
formed upon treatment of HL-60 cells with H1 mushroom extract. Extract-induced activation 
of caspase-6 already occurred after 12 hs and reached its maximum after 36 hs.  
pro-caspase 6 
cleaved caspase 6 
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24h 12h 
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actin 
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Activation of caspase-7 was later induced as depicted in Figure 13. HL-60 cells incubated 
with mushroom extract got no signal of the mature subunit after 24 hs. A small amount of the 
cleaved active form of caspase-7 was present at 36 h and increased further after 48 hs. These 
data suggested that our mushroom extract induced apoptotic cell death via not only the 
activation of caspase-3 but also via the activation of caspase-6 and caspase-7. 
 
 
 
Figure 13: H1 mushroom extract induces activation of caspase-7. HL-60 cells were incubated with 
the indicated concentrations of mushroom extract for 12 hs, 24 hs, 36 hs and 48 hs. Western blot analysis 
showed the activation of caspase-7 resulting in time-dependent and concentration-dependent appearance of the 
p20 subunit. After being exposed, the membrane was stripped and blotted with anti-Actin antibody as a loading 
control. 
 
Because caspase-3 is the most prominent downstream effector caspase, caspase-3 processing 
could happen via two different signaling pathways: (i) the death receptor-mediated signaling 
or (ii) the activation of mitochondria. We next examined these two possibilities by detecting 
caspase-9 subunit (p20) since detection of caspase-9 subunits would indicate processing of 
caspase-3 via the mitochondria signaling pathway. As shown in Figure 14, procaspase-9 was 
partly cleaved and the level of its active form increased time-dependently in HL-60 cell lines, 
actin 
pro-caspase 7 
cleaved caspase 7 
1.0 1.5 0.5 0 1.0 1.5 0.5 0 H1 mushroom extract (mg/ml) 
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actin 
35 kDa -- 
20 kDa -- 
35 kDa -- 
20 kDa -- 
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being especially significant after 36 hs and 48 hs, indicating that induction of the apoptotic 
cascade occurs via the mitochondrial signaling pathway.  
 
 
 
Figure 14: H1 mushroom extract induces activation of caspase-9. HL-60 cells were incubated with 
the indicated concentrations of mushroom extract for 12 hs, 24 hs, 36 hs and 48 hs. Western blot analysis 
showed the activation of caspase-9 resulting in time-dependent and concentration-dependent appearance of the 
p17 subunit. After being exposed, the membrane was stripped and blotted with anti-Actin antibody as a loading 
control. 
 
To confirm this, mitochondrial potential alteration was examined upon mushroom treatment. 
Cytosolic-specific, mitochondria-free protein lysates were prepared. The release of cytochrom 
c from mitochondrial to cytoplasm was showed by visualising protein level of cytochrom c of 
cytosolic fraction by Western blot. As illustrated in Figure 15, treatment with H1 extract 
caused an increase of cytochrom c in the cytosolic fraction after 24 hs and more pronounced 
after 36 hs and 48 hs. Taking together, these results indicate that H1 extract potentially 
induces the mitochondrial, intrinsic pathway of apoptosis in HL-60 leukeamia cell line.  
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Bcl-2 expression was also analyzed but neither increase nor reduction of bcl-2 expression was 
detected (data not shown). 
 
 
 
Figure 15: The cytochrome c protein level of cytosolic fractions of HL-60 cells treated with H1 
mushroom extract. HL-60 cells were incubated with the indcated concentrations of H1 extract for 12 h, 24 h, 36 
h and 48 h. Western blot analysis shows the presence of cytochrom c in cytosolic fractions after release of 
cytochrom c from mitochondria. 
 
However, detection of a drug-induced permeability shift of mitochondria and activation of 
caspase-9 does not exclude the possibility of a parallel induction of the death receptor 
pathway. Caspase-8 is the initiator caspase in this pathway therefore activities of caspase-8 
was determined by Western blot analysis (Figure 16). Caspase-8 is synthesized as an inactive 
precursor of 55 kDa, which was detected as a double protein band, representing the isoforms 
procaspase-8a and procaspase-8b, and due to the induction of apoptosis, it was followed by 
the formation of a 43-kDa, 41-kDa intermediate cleavage product, processed to a p18 
heterodimer. Interestingly, here in our case, the formation of intermediate cleavage products 
p43/p41 was evident while no mature caspase-8 subunit p18 was observed. 
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Figure 16: H1 mushroom extract induces activation of caspase-8. HL-60 cells were incubated with 
the indicated concentrations of mushroom extract for 12 hs, 24 hs, 36 hs and 48 hs. Western blot analysis 
showed the activation of caspase-8 resulting in time-dependent and concentration-dependent appearance of the 
p42/p41 subunit. After being exposed, the membrane was stripped and blotted with anti-Actin antibody as a 
loading control. 
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III.6. Proteome analysis of apoptosis induced by H1 mushroom 
extract in HL-60 cells 
 
High resolution 2DE-PAGE and DIGE were used to identify proteins associated with 
apoptosis and other cellular pathways in HL-60 cells upon treatment of our mushroom extract. 
The basic requirement for reliable image analysis is the reproducibility of a series of good-
quality 2-DE gels with low background staining. 2-DE gels of both protein lysates of 
untreated and treated cells from at least 3 different biological samples were prepared and 
compared.  
 
Figure 17: DIGE analysis of proteins from mushroom extract treated cells.  Proteins of HL-60 cells 
treated with 1mg/ml H1 extract (Cy5, red) were compared with those of control sample (Cy3, green) by 2D-
DIGE using 24-cm pH 3-11 IPG strips and a 12.5 % SDS-PAGE gel. Orientation of the pH gradients are 
indicated on the horizontal axes and approximately apparent molecular mass ranges are indicated along the 
vertical axes. Proteins increased upon treatment appear red and those repressed by H1 extract appear green, 
whereas those unaffected appear yellow.  
 
The visual evaluation aimed for obviously intensity-different spots, especially spot which 
appeared on gels of one sample but not the other sample because such differences were more 
likely associated with apoptosis and were not the consequence of differences in sample 
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concentration or in the staining process. Therefore, only spots consistently regulated in all 
preparations were considered differentially expressed and chosen for further analysis. 
Abundance ratio (as reported in table 3) was acquired as changes between Cy5 (treated) and 
Cy3 (untreated) gel images relative to the internal reference (Cy2). 
Paired treated and control samples were combined and separated on the same 2D gel. Each 
gel was then sequentially scanned at the wavelengths specific for each fluorescent label and 
the images were overlaid digitally. The overlaid pattern (Cy3, Cy5 and Cy2) of protein spots 
generated in a non-linear pH 3-11 gradient immobilized pH gradient (IPG) strip was shown in 
Figure 17. This might be considered as a general picture of the merged proteomic profile of 
HL-60 control cell and HL-60 cell treated with H1 extract. Fluorescent green and red spots 
indicated spots of repressed and increased proteins upon treatment, respectively. Yellow spots 
reflect no significant change in protein regulation. Significant changes (+/- 1.4 fold in our 
case) in spot intensity were manually validated. The expression pattern was highly 
reproducible, however, minor differences in spot intensity were observed for few spots from 
gel to gel.  
Several significantly altered spots have been detected in both untreated and treated cells. 
Altered spots were excised from preparative gels, digested with trypsin and mass 
spectrometric analysis was performed. Results of data bank searches and their degree of 
regulation were given in Table 3 and positions of corresponding spots on gels are shown in 
Figure 18. Enlarged 2D-view and 3D-view of certain altered spots are shown in Figures 19, 
20 and 21. 
The majority of spots were successfully identified only a few spots were unidentified due to 
low protein abundance. Among spots which were reproducibly detected, 29 were changed by 
H1 mushroom extract in comparison to the control (greater or equal to 1.4 fold). These 29 
differently expressed proteins sequenced by MALDI-TOF-MS are listed in Table 3. 
Significant decrease of intensity was detected for heat shock protein beta 1, nucleoside 
diphosphate kinase whereas spot intensity was obviously increased for fragments of alpha-
enolase, heterogeneous nuclear ribonucleaoprotein F, Rho GDP dissociation inhibitor 2 (D4-
GDI) and phosphatidylethanolamine-binding protein 1.  
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SwissProt  Abundance Protein 
(1) Accession 
no. (2) 
Description 
(3) 
mW 
(Da) 
(4) 
pI (pH) 
(5) 
PLGS 
score 
(6) 
Probability 
(%) (7) 
Peptides 
(8) 
Coverage 
(%) (9) Ratio (10) 
Biological function 
(11) 
NDKA P15531 
Nucleoside diphosphate 
kinase A 17137 5,7662 11,4181 34,44 7 51,9737 -2,9 Antimetastatic activity 
PEBP1 P30086 
Phosphatidylethanolamine-
binding protein 1 21043 7,3889 12,4482 96,48 9 58,2888 2,72 Binding protein 
GDIS P52566 
Rho GDP dissociation 
inhibitor 2 22973 4,8983 8,1 1,25 5 29,8507 3,41 
Cell communication & 
signal tranduction 
HSP7C P11142 
Heat shock cognate 71 kDa 
protein 70854 5,1998 10,4181 12,67 18 33,5913 2,1 
Cellular transport & 
chaperoning 
HSPB1 P04792 Heat shock protein beta 1 22768 5,9588 12,484 100 7 37,561 -2,36 
Cellular transport & 
chaperoning 
TBB5 P07437 Tubulin beta chain 49638 4,5903 10,2614 10,83 12 29,0541 -1,7 
Cell structure and related 
proteins 
VIME P08670 Vimentin 53619 4,8629 11,9875 60,86 31 60,9442 -1,69 
Cytoskeleton 
conformation 
ENOA P06733 Alpha-enolase 47139 7,1713 12,0106 62,28 16 43,318 2,25 
Glycolysis, ATP 
generation & transport 
ALDOA P04075 
Fructose-bisphosphate 
aldolase A 39395 8,0645 10,8009 18,58 14 43,1319 1,64 
Glycolysis, ATP 
generation & transport 
PGAM1 P18669 Phosphoglycerate mutase 1 28785 6,7861 11,2638 29,52 10 57,0866 1,83 
Glycolysis, ATP 
generation & transport 
G3P P04406 
Glyceraldehyde-3-
phosphate dehydrogenase 36030 8,6966 11,8621 53,69 10 35,2239 1,5 
Glycolysis, ATP 
generation & transport 
PRDX6 P30041 Peroxiredoxin-6 25019 5,9572 11,4671 36,17 11 52,6786 1,99 Lipid degradation 
AK1A1 P14550 
Alcohol dehydrogenase  
NADP 36549 6,3384 12,4684 98,45 9 30,1538 1,64 
Metabolism, energy 
pathway 
NUP50 Q9UKX7 Nucleoporin 50 kDa 50113 6,6951 10,7506 17,67 11 33,1197 -1,6 
Nucleoctoplasmic 
transport 
HNRH1 P31943 
Heterogeneous nuclear 
ribonucleoprotein H 49198 5,8513 11,7884 49,88 16 44,098 -1,88 RNA metabolism 
HNRPF P52597 
Heterogeneous nuclear 
ribonucleoprotein F 45642 5,2414 11,6551 43,65 12 40,9639 -1,41 RNA metabolism 
HNRPL P14866 
Heterogeneous nuclear 
ribonucleoprotein L 60149 6,6826 12,4819 99,79 16 29,7491 1,55 RNA metabolism 
 
ROA1 
 
P09651 
Heterogeneous nuclear 
ribonucleoprotein A1 
 
38822 
 
9,4587 
 
11,3823 
 
33,23 
 
9 
 
30,1075 
 
-1,82 
 
RNA metabolism 
ROA3 P51991 Heterogeneous nuclear 39570 9,2212 11,3836 33,27 11 31,2169 -1,85 RNA metabolism 
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(1) (2) (3) (4) (5) (6) (7) (8) (9) (10) (11) 
HNRPM P52272 
Heterogeneous nuclear 
ribonucleoprotein M 77464 9,0037 12,3299 85,72 21 31,3699 -1,41 RNA metabolism 
STIP1 P31948 
Stress-induced-
phosphoprotein 1 62599 6,3858 12,3634 88,64 10 23,0203 1,61 Stress response 
CH60 P10809 
60 kDa heat shock protein  
mitochondrial precursor 61016 5,5503 12,4685 98,46 19 40,8377 1,7 Stress response 
PDIA3 P30101 
Protein disulfide isomerase 
A3 precursor 56746 5,9299 11,3866 33,37 19 36,6337 1,47 Stress response 
F10A1 P50502 Hsc70-interacting protein 41305 4,9966 11,4949 37,19 10 27,6423 1,87 Stress response 
TCPE P48643 
T-complex protein 1 subunit 
epsilon 59632 5,3036 11,476 36,49 20 32,1627 1,29 Stress response 
CATA P04040 Catalase 59718 6,9716 12,4711 98,72 16 34,1556 1,53 
Stress response, 
antioxiant enzyme 
FUBP1 Q96AE4 
Far upstream element 
binding protein 2 67518 7,4264 12,4785 99,45 17 29,6584 -1,56 Transcription 
IF32 Q13347 
Eukaryotic translation 
initiation factor 3 subunit 2 36478 5,2615 11,5989 41,27 11 38,4615 -1,6 Translation initation 
MDHM P40926 
Malate dehydrogenase  
mitochondrial precursor 35508 8,8202 11,6093 41,7 14 51,4793 1,81 Tricarboxylic, acid cycle 
           
 
Table 3: Altered spots identified by mass spectrometric analysis. 
 
 
 
 
 
rebinucleoprotein A3 
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Figure 18: Proteome 
maps indicating the 
position of altered 
proteins identified. 
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Figure 19: Enlarged 2D-view and 3D-view of altered spots of proteins which have stress reponse or 
chaperone function 
 
             
 
Figure 20: Enlarged 2D-view and 3D-view of altered spots of proteins which belong to HNRP protein 
family. 
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Figure 21: Enlarged 2D-view and 3D-view of altered spots of proteins which involved in glycolysis 
and tricarboxylic acid cycle. 
 
Differently expressed proteins identified are involved in various cellular processes. Heat shock 
cognate 71 kDa protein (HSP7C), heat shock protein beta 1 (HSPB1), stress-induced-
phosphoprotein 1 (STIP1), 60 kDa heat shock protein mitochondrial precursor (CH60), Protein 
disulfide isomerase A3 precursor (PDIA3), Hsc70-interacting protein (F10A1), T-complex 
protein 1 subunit epsilon (TCPE) and catalase (CATA) play roles in stress response, cellular 
transport and chaperone (Figure 19). Involved in RNA metabolism are the Heterogeneous 
nuclear ribonucleoprotein family including the heterogeneous nuclear ribonucleoprotein H, F, L, 
A1, A3 and M (Figure 20). Another large group is the group of proteins essential for  glycolysis, 
ATP generation and transport, such as alpha-enolase (ENOA), fructose-bisphosphate aldolase A 
(ALDOA), phosphoglycerate mutase 1 (PGAM1) and glyceraldehydes-3-phosphate 
dehydrogenase (G3P) (Figure 21); protein metabolism; DNA repair; cell structure; cell 
communication and signal transduction, etc. 
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III.7. Cleavage of D4-GDI upon treatment with H1 mushroom extract 
 
One of the most variable spots was identified as D4-GDI (GDIS). This alteration was 
reproducible although searches on data bank showed very low probability as shown in Table 3. 
The effect of mushroom extract on the expression of Rho guanine nucleotide dissociation 
inhibitor (GDI) 2 found in proteomic study was confirmed by western blotting using a rabbit 
polyclonal antibody. As illustrated in Figure 22, in the untreated sample, the 27/28-kDa band 
was obvious while nearly no signal was detected for the 23-kDa band. D4-GDI cleavage was 
induced after 36 hs upon treatment with H1 mushroom extract. The 27-kDa D4-GDI band was 
specifically cleaved to a 23-kDa fragment. The uncleavable 28-kDa Rho-GDI and the uncleaved 
27-kDa D4-GDI appear as a single band in the Western blot, which can only be resolved by short 
exposure time. 
 
   
 
                                             
                                                
 
Figure 22: H1 mushroom extract induces cleavage of D4-GDI. HL-60 cells were incubated with the 
concentration 1mg/ml of mushroom extract for 36 hs. Cell lysates were prepared and analyzed by Western blotting 
using a Rho-GDI-specific polyclonal antiserum (which cross-reacts with D4-GDI). The first arrow on the right 
pointed out the 27-kDa D4-GDI and the 28-kDa Rho-GDI band. Western blot analysis showed the cleavage of D4-
GDI resulting in the appearance of the 23-kDa cleavage product. After being exposed, the membrane was stripped 
and blotted with anti-Actin antibody as a loading control. 
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III.8. miRNA expression level analysis in HL-60 treated with H1 
mushroom extract 
 
After getting information about the proteomic profile of HL-60 cells upon treatment with H1 
mushroom extract, in order to gain insights into the signaling cascades, it is essential to 
understand the regulatory machine in which miRNAs act as one of the most crucial part. 
MicroRNAs represent a new class of gene products, which are believed to specifically control 
the translation and stability of target mRNAs based on (partial) sequence complementarity. They 
play an important role in many biological processes. There are up to date about more than 800 
miRNAs identified in Homo sapiens (according to miRBase), but biological roles of not many of 
them have been experimentally validated. Determining specific expression patterns for miRNAs 
of cells in different conditions would provide important evidences regarding their regulatory 
functions. Moreover, data about distinct miRNA expression patterns would be very useful in 
investigating predicted mRNA targets of different miRNAs and also the interrelation between 
the differentiation in protein expression and miRNA expression.  
In order to obtain the differential expression information for miRNAs from human leukeamia 
HL-60 cells upon treatment with mushroom extract, miRNA expression was evaluated by micro 
array and real-time RT-PCR analysis. Total RNA which was isolated from untreated cells and 
cells treated with mushroom extract was prepared and probed by real-time RT-PCR or used for 
miRNA enrichment for further screening by micro array.  
Comparison between H1 mushroom extract-treated sample and untreated sample resulted in 
large differences in miRNA expression profile. Utilising NCode Multi-Species miRNA micro 
array, 50 miRNAs were detected (as shown in Figure 23). Strikingly, expression of 16 miRNAs 
in the mushroom-treated versus untreated sample has been changed by more than 2-fold. 
One of the features of miRNAs is that they can occur in clusters on the genomic DNA that are 
co-expressed [Lagos-Quintana et al., 2001; Lau et al., 2001]. Our micro array analysis revealed 
that such miRNAs were also co-expressed and found in clusters: such as 15b-cluster (including 
hsa-miR-15b and hsa-miR-16-2), 16-1-cluster (including hsa-miR-16-1 and hsa-miR-15a), 25-
cluster (including hsa-miR-25, hsa-miR-93 and hsa-miR-106b) and 17-cluster (including hsa-
miR-17, hsa-miR-18, hsa-miR-19a, hsa-miR-19b, hsa-miR-20 and hsa-miR-92). Expression 
patterns of individual miRNA in each cluster are relatively similar indicating that these clustered 
miRNA families are not regulated upon mushroom extract treatment. 
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Figure 23: Comparative expression of miRNAs in HL-60 (mushroom extract-treated versus untreated sample). Bars represent deviations from mean expression levels 
for each miRNA on a log2 scale. 
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It has been reported that several miRNAs were strongly expressed in specific tissues, for 
instance, miR-1 variants in heart, miR-122 variants in liver or miR-124 variants in brain [Lee, 
2001]. miRNAs which are specific for cells which belong to haematopoietic tissue, including 
miR-142-3p, miR-155, miR-181, and miR-223 [Ramkissoon et al., 2006] usually expressed at 
high levels in our micro arrays. In addition, let-7 miRNA variants, miR-16, miR-21, miR-26a 
which are abundant in many tissues or cells [Lagos-Quintana et al., 2003] also appeared in 
our micro arrays. 
hsa-miR-224, hsa-miR-337, hsa-miR-378 and mmu-miR-698 exhibited a relatively high level 
of alteration in mushroom-treated versus untreated sample. U6 was used as a control to 
indicate ubiquitous miRNA expression. 
 
                   g  c              ugu      ccu  
   agg cu cugacuccaggucc   guguua   a 
   ||| || ||||||||||||||   ||||||     
   A.  ucc ga gacugagguucagg   cacgau   g 
      g  a              --u      aaa  
 
                    B.                 
0
0,2
0,4
0,6
0,8
1
1,2
C- H1
R
Q
 
        
Figure 24: hsa-miR-378 expression upon treatment of H1 mushroom extract in human leukeamia 
cell HL-60. A. Homo sapiens miR-378 stem-loop with mature sequence in red. B. Expression of has-miR-378 in 
untreated (sample C-) and treated (sample H1) human leukeamia cell HL-60 assessed by miRNA-specific real-
time qRT-PCR.  
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To verify miRNA expression, selected miRNAs were chosen and their relative expression 
levels were quantified using real-time RT-PCR. Notably, a close relation between real-time 
RT-PCR and microarray was found. The differences in expression of hsa-miR-338 and hsa-
miR-378 evaluated by real-time RT-PCR were shown here.  
As depicted in Figure 24, hsa-miR-378 (previously called has-miR-422b) has been identified 
as the most abundant miRNA cloned from human leukeamia HL-60 cells [Kasashima et al., 
2004]. hsa-miR-378 was expressed strongly in untreated HL-60 cells whereas only quite weak 
signal was detected upon treatment with mushroom extract. 
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Figure 25: hsa-miR-338 expression upon treatment of H1 mushroom extract in human leukeamia 
cell HL-60. A. Homo sapiens miR-338 stem-loop with mature sequence in red. B. Expression of has-miR-338 in 
untreated (sample C-) and treated (sample H1) human leukeamia cell HL-60 assessed by miRNA-specific real-
time qRT-PCR. 
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The difference in expression of hsa-miR-338 was also confirmed by real-time qRT-PCR. In 
contrast, the level of expression of hsa-miR-338 was over-expressed upon mushroom 
treatment, as depicted in Figure 25.  
In summary, 16 differently expressed miRNAs were detected in an effort to provide a more 
comprehensive view into molecules of the regulatory machine of HL-60 cells upon treatment 
with H1 mushroom extract. This is important to understand the posttranscriptional regulation 
of gene expression. 
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IV. DISCUSSION 
 
Here in our study, many evidences about molecular mechanisms of apoptosis induced in HL-
60 upon treatment of water-soluble extract of tropical medical mushroom Phellinus 
pachyphloeus are elucidated. 
Medical mushrooms such as Ganoderma lucidum, Lentinus edodes and many others have 
historically been used to remedy different diseases in eastern traditional folk medicine and 
ethno-pharmacology. Many traditionally used mushrooms have been explored for novel 
medical properties and have evoked considerable interest as anti-tumour agents especially in 
the context of apoptosis induction [Wasser, 2002]. 
Apoptosis is a defined program of cell death that is markedly influenced both positively and 
negatively by a variety of genes, many of which are mutated and/or dysfunctionally regulated 
in human cancers [McGill & Firscher, 1997] and therefore is a very important aspect in 
cancer treatment. There are many reports regarding the ability of mushrooms to induce 
apoptosis in various tumour models [Hsieh et al., 2006; Sliva et al., 2008; Müller et al., 
2006].  
Within the framework of our project we focused on Phellinus pachyphloeus which is an 
abundant tropical mushroom [Wagner & Firscher, 2002]. Many species of the Phellinus genus 
such as P. igniarius, P. robustus and P. linteus are reported to possess anti-tumour activities 
[Song et al., 2008; Ajith & Janardhanan, 2007; Choi et al., 2004]. Phellinus pachyphloeus has 
often been used in the form of aqueous extract in eastern traditional folk medicine but no 
attempt has been made so far to elucidate its molecular properties. Therefore, in this study we 
investigated the molecular action of identical aqueous extracts in HL-60 human leukeamia 
cell line. Of special interest was the elucidation of the molecular action of crude water-soluble 
extract from P. pachyphloeus to govern anti-proliferation, cell cycle and apoptosis in HL-60 
human promyelocytic leukaemia cells. Moreover, expression of an abundance of specific 
molecular targets concerning these processes such as apoptogenic/anti-apoptotic and 
extracellular signalling regulatory proteins and related miRNAs upon treatment with 
mushroom have unveiled. 
Crude water-soluble extract, not fractionated compounds and substances, have been long used 
in eastern traditional medicine. Results from many investigations suggested that constituent 
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compounds from crude extracts could potentially have synergistic effects in the prevention 
and treatment of cancer while their action could also interfere with each other’s [Borschers et 
al., 2004]. In our study, we also used crude water-soluble extract of P. pachyphloeus without 
further fractionation. 
Many investigators doubt that wild mushrooms may be contaminated with toxic metals such 
as arsenic, lead, cadmium as well as radioactive substances because many mushrooms have 
the ability to accumulate relatively high concentrations of heavy metals [Borschers et al., 
2004]. Therefore, before performing all other experiments, our extract was tested for the 
heavy metals’ content. Amounts of heavy metals at even the highest extract concentration we 
used for experiments were much lower than allowed levels. Extract in the concentration range 
of treatment showed no cytotoxic effect in HL-60 and other cell lines such as Hela, Vero-B4, 
etc. (data not shown). But it could significantly dose-dependently suppress the proliferation of 
HL-60 cells in vitro. 
There are many reports showing that crude water extract of many medical mushrooms inhibit 
cell proliferation of several kinds of cell lines through apoptosis induction [Wasser, 2002]. 
Aqueous extract from Agaricus blazei inhibited the growth of human gastric epithelial AGS 
cells through cell cycle arrest at the G2/M phase and the induction of caspase-3-dependent 
apoptosis [Jin et al., 2006]. Ganoderma lucidum inhibited the growth of MDA-MB-231 breast 
cancer cells by modulating Akt/NF-κB signaling [Jiang, 2004]. Phellinus linteus, another 
well-known medical mushroom which belongs to the same genus as ours, induced apoptosis 
in human neuroblastoma cell by caspase-3 activation through an up-regulation of bax [Choi et 
al., 2004]. From results reported here it was clear that antiproliferative activity of our 
mushroom extract was manifested by induction of apoptosis determined by the presence of 
sub-G1 peak with flow cytometry measurement and by DNA laddering.  
We attempted to clarify which pathway – the death receptor (extrinsic) or the mitochondrial 
(intrinsic) pathway – was involved in P. pachyphloeus extract – induced apoptosis. In the 
intrinsic pathway, apoptosis inducers cause release of cytochrome c from mitochondria which 
consequently activate caspase-9 and caspase-3, the latter then triggers apoptosis. The extrinsic 
pathway is caused by the direct interaction between so-called “death ligands” and “death 
receptors”, in which caspase-8 is activated [Debatin, 2004]. It seems that apoptosis caused by 
extracts from mushrooms is regulated through intrinsic pathway [Kim et al., 2007]. Aqueous 
extracts of I'm-Yunity (PSP) inhibited cell proliferation and induced apoptosis in HL-60 and 
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U-937 cells accompanied by the expression of anti-apoptotic proteins bcl-2 and survivin, the 
increasing in apoptogenic proteins bax and cytochrome c, and the cleavage of poly (ADP-
ribose) polymerase (PARP) [Hsieh et al., 2006]. In HL-60 cells, the activation of caspase-3, 
caspase-6, caspase-7, caspase 8, and caspase-9 was observed upon treatment with P. 
pachyphloeus mushroom extract. So both the activation of a proximal caspase, such as 
caspase-8 for extrinsic receptor-mediated apoptosis and caspase-9 for intrinsic mitochondrial-
mediated apoptosis were observed. Western blotting analysis also revealed the release of 
cytochrome c. This further supports our current suggestion that apoptosis induction by our 
mushroom extract is mediated via both intrinsic and extrinsic pathways.  
 
Figure 26: Funtional classification of differentially expressed proteins identified from cells upon 
treatment with H1 mushroom extract. For each category the numbers of up- & down-regulated proteins are 
indicated by arrows. 
 
To understand the mechanism of apoptosis induced by mushroom extract, we checked the 
possible molecular targets upon treatment with the extract in HL-60 by proteomics 
experiments. The DIGE technique has been proved to be a highly sensitive and dynamic 
method which facilitated the detection of significantly regulated proteins from HL-60 cells 
upon treatment with H1 mushroom extract. Our proteomic study revealed 29 proteins with 
differentially regulated expression levels in cells treated with mushroom extract and the 
control. These proteins play important roles in variety of pathway including stress response, 
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cytoskeleton, ATP synthesis, RNA metabolism, etc (Table 3). The data about functions of 
these proteins was represented as a pie chart above (Figure 25). This was based on i) the 
extent to which the protein was up- or down-regulated and ii) a detailed investigation into 
their currently known roles as described in the scientific literature.  
The most differently expressed protein spots of cells treated with mushroom extract and 
untreated cells were identified as various heterogeneous nuclear ribonucleoprotein (hnRNPs) 
and Rho guanine nucleotide dissociation inhibitor (GDI) 2.  
Rho-GDI 2 was identified up-regulated in the mushroom extract-treated sample comparing to 
untreated one. Rho-GDI 2 is a GDP dissociation inhibitor for the Ras-related Rho family 
GTPase in haematopoietic cells during apoptosis and the cleavage of Rho-GDI 2 has been 
demonstrated during CD95/Fas-induced apoptosis and occurs by a caspase-3-dependent 
mechanism [Na, 1996]. Rho-GDI 2 was found more than 2 fold increase of expression as well 
in mouse spleen mononuclear cells treated with polysaccharides from spores of Ganoderma 
lucidum [Ma et al., 2008]. Rho-GDI 2 is regulated during apoptosis induced by daunorubicin, 
an anti-cancer drug, in HL-60 cells through the activation of caspase-3 [Kwon et al., 2002]. 
Owing to its crucial role as a modulator of Rho GTPase, this might in turn have a significant 
impact on the mechanisms that induce the cytoskeletal and morphological changes in 
apoptotic cells. 
Heterogeneous nuclear ribonucleoproteins (hnRNP) have central roles in DNA repair, cell 
signalling and in regulating gene expression at both transcriptional and translational levels 
and changes of balance among hnRNPs can contribute to apoptosis induction [Carpenter et 
al., 2006]. Upon treatment with our mushroom extract, six hnRNPs was identified to be 
altered after induction of apoptosis: hnRNP L were up-regulated and hnRNP A1, A3, F, H 
and M were down-regulated. Involvement of hnRNP proteins have been demonstrated for the 
hnRNPs A0, A1, A2/B1, A3, C1/C2, R and U [Brockstedt et al., 1998; Waterhouse et al., 
1996; Thiede et al., 2001]. HnRNP A1 is a dephosphorylated protein that might be cleaved 
into different cleavage products after apoptosis induction [Hermann et al., 2001]. 
Treatment with extract from P. pachyphloeus also caused the up-regulation of several proteins 
such as alpha anolase, phosphoglycerate mutase 1, phosphoglycerate kinase 1, and adenylate 
kinase isoenzyme 2 which play a role in glycolysis, ATP generation and transport [López-
Pedrera et al., 2006]. It is known that increased rates of glycolysis are generally found in 
tumour cells [Przybytkwoski et al., 2007]. But here we monitored the opposite direction of 
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regulation. This might be explained due to the large content of polysaccharides that are 
present in our extract.  
There are some common aspects between apoptosis induced by our mushroom extract and 
apoptosis induced by staurosporine. Apoptosis induction by both resulted in up-regulation of 
heat shock cognate 71, stress-induced phosphoprotein 1 and protein disulfide isomerase A1 
precursor and in down-regulation of vimentin [Short et al., 2007]. Protein disulfide isomerase 
A3 precursor and stress-induced phosphoprotein 1 play important roles in stress response. 
Heat shock cognate 71 (hsp70) and protein disulfide isomerase are endoplasmic reticulum 
chaperone. Several reports emphasize chaperones have a complex role in apoptosis. Although, 
the cytoprotective effect of hsp70 is related to their ability to disable apoptosis [Garrido et al., 
2006], our study indicates that there is an inverse relationship between the level of hsp70 and 
the rate of apoptosis induced by HL-60 upon treatment of mushroom extract. There are also 
reports that hsp70 can promote receptor-mediated apoptosis [Liossis et al., 1997]. On the 
other hand, in non-muscle cells, vimentin is one of the characteristic proteins of intermediate 
filaments [Izdebsja, 2006]. Vimentin is rapidly proteolyzed by multiple caspases into similar 
sized fragments during apoptosis induced by many stimuli [Byzn et al., 2001]. Caspase 
cleavage of vimentin disrupts its cytoplasm network of intermediate filaments and coincides 
temporally with nuclear fragmentation [Morishima, 1999]. Moreover, it has become 
increasingly clear that the induction of apoptosis in tumour cells can occur by at least three 
different pathways involving the cell surface receptors, the mitochondria and the endoplasmic 
reticulum [Cory & Cory, 2007]. Taken together, our findings suggested that endoplasmic 
reticulum stress pathway also might involve in mushroom extract-induced apoptosis. 
Also, although the 2D DIGE separation technology is capable of resolving several thousand 
individual protein spots on a single gel, not all proteins were resolved because of extremes of 
size or pI, or because of gel feature overlap in some areas. Furthermore, many low-abundance 
proteins were presumably not detected. Some of these limitations could be addressed by 
altering separation techniques to increase resolution (e.g., by using narrow-range pI 
separations or various acrylamide concentrations). Finally, some of the proteins might have 
been detected on the gels but not identified by MS. Improvements in the sensitivity of MS 
techniques and/or improved database searching algorithms should reduce identification 
failures in the future. 
Furthermore, we have identified several miRNAs differentially expressed in human leukaemia 
HL-60 cells upon treatment with H1 mushroom extract.  
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MicroRNAs (miRNAs) belong to a new class of regulators of gene expression. Initially 
discovered as regulators of developmental timing in invertebrates [Lee et al., 1993], miRNAs 
have subsequently been implicated in a variety of biological processes including proliferation, 
differentiation and also in apoptosis [Alvarez-Garcia & Miska, 2005; Wienholds & Plasterk, 
2005; Carthew, 2006]. Several recent studies have shown many evidences for the involvement 
of miRNAs in cancers and also indicated that miRNAs play important role in cancer 
formation and regulate cell growth and apoptosis [Stefani, 2007].  
As reviewed by Park and Peter [Park & Peter, 2008], studies in many tissues have revealed 
that there are miRNAs with pro- or anti-apoptotic functions. While miR-34 [Chang et al., 
2007], miR-15a, miR-16-1 [Cimmino et al., 2005] and miR-29 [Mott et al., 2007] represent 
examples of miRNAs which show pro-apoptotic function; miR-21 [Chan et al., 2005], part of 
miR-17-92 cluster [Matsubara et al., 2007] have been proposed to inhibit apoptosis. In our 
micro array screening, these miRNAs expressed but expression levels of them were not much 
changed. Furthermore, in present study, miRNAs which are specific for hematopoietic cells 
such as miR-142, miR-155, miR-181, miR-223 [Ramkissoon et al., 2006] also expressed at 
high level in human leukeamia HL-60 cells.  
Upon treatment of our mushroom extract, while miR-337 over-expression has been clearly 
observed, the most highly down-regulated miRNAs were miR-224, miR-378 and miR-698. 
These regulation differences were shown in our microarray experiment and then confirmed by 
real-time PCR. When performing searching capable targets for these miRNAs in 
microRNA.org [Betel et al., 2008], we found that some of our differently expressed proteins 
are also their targets. Phosphoglycerate mutase 1 and Fructose – biophosphate aldolase A 
which have been found over-expressed are targets of the down-regulated miR-378. Catalase 
and heterogeneous nuclear ribonucleoprotein K are negatively regulated by miR-224. 
Heterogeneous nuclear ribonucleoprotein A3 which shows down-regulated has target 
sequence for both miR-338 and miR-224. 
Murakami et al. [Murakami et al., 2006] investigated miRNA expression profiles of 
hepatocellular carcinoma (HCC) and adjacent nontumourous tissue and found that miR-224 
was significantly over-expressed in HCC compared with nontumour tissues. miR-224 
expression was further found to be inversely correlated with apoptosis inhibitor-5 (API-5) 
expression in HCC patients [Wang et al., 2008]. miR-224 was also shown to be over 
expressed in prostate tumours with perineural invasion compared to those without it [Prueitt et 
al., 2008]. Our finding identified and validated miR-224 down-regulation in HL-60 after 
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treatment with mushroom extract. This outcome strongly suggests that miR-224 plays 
important role in proliferation and differentiation of several cancers. 
The involvement of miR-378 in HL-60 was previously indicated by Karashima et al. 
[Karashima et al., 2004], in this study, miR-378 was firstly named miR-422b. 12-O-
tetradecanoylphorbol-13-acetate (TPA) was first found in the croton plant, is diester of 
phorbol and being studied as a drug in treatment of heamatologic cancer [Ito et al., 2001; 
Laouar et al., 2001]. However, miR-378 was detected almost equally in the TPA (-) and TPA 
(+) samples. Expression of miR-378 has been also reported to enhance cell survival, reduce 
caspase-3 activity and promote tumour growth and angiogenesis [Lee et al., 2007]. So miR-
378 may play important role in caspase-3-dependent apoptosis fashion in HL-60 treated with 
mushroom extract.  
In summary, the expression of many miRNAs was regulated in HL-60 upon treatment of P. 
pachyphloeus aqueous extract. Both up-regulated and down-regulated expression patterns 
were observed, depending on the miRNA in question. Precise mechanism concerning this 
regulation remains unknown and warrants further investigation. 
 
Outlook 
In present study, aqueous extract from Phellinus pachyphloeus was shown to induce apoptosis 
in human leukaemia cell line through the activation of the caspase cascade via both death 
receptor and mitochondrial signalling pathway. Many bioactive compounds and substances, 
including glucans, glycoproteins, lectins, etc., have been found from aqueous extracts of many 
other tropical medical mushrooms. But there are also opinions that compounds in the extracts 
act synergistically to potentiate their bioactivity. Considerably more work is needed to be 
done to investigate whether constituent compounds in our mushroom extract have synergistic 
effects or there are individual compounds which possess anti-tumor properties. Further 
fractionations of the extract and bioassay tests remain to be done. 
On the other hand, what is now also needed are further studies to establish more in detail 
about the correlation between proteins and miRNAs which have been found to differentially 
expressed upon treatment with our mushroom extract. These studies will help us to see more 
precisely behind the curtain about the entire mechanisms of response of human cells upon 
treatment with extracts from tropical medical mushrooms, including Phellinus pachyphloeus. 
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V. SUMMARY 
 
Despite the availability of several therapeutic options, a safer and more effective approach is 
urgently sought for treatment of cancer. Numerous novel anticancer agents are being 
discovered from eastern traditional folk medicine and ethno-pharmacology. Besides plants, 
mushrooms represent a significant source of bioactive compounds for the development of 
therapeutics by the pharmaceutical industry. Presently, studies on the bioactive components of 
medical mushrooms are mainly focused on polysaccharides, triterpenes and steroid 
compounds which contain in water- or alcohol-soluble extracts. Although many 
pharmaceutical properties, emphatically the anti-tumour properties, of several medical 
mushrooms were extensively investigated, sufficient scientific studies have not been 
performed to characterize the molecular mechanisms by which medical mushrooms exert their 
activities. Many reports showed that mushrooms possess the ability to stimulate mononuclear 
cell activation, spleen cell proliferation, and cytokine expression; to modulate anti-
proliferative effects on many cancers; to regulate cell cycle and induce apoptosis in cancer 
cell lines. However, the majority of these observations often lack standardization and still 
based on phenomenology. So considerable understanding in molecular level remains to be 
determined. 
In the present study, pharmaceutical properties of a tropical and subtropical, abundant, wood-
decaying mushroom Phellinus pachyphloeus (Pat.) Pat. were investigated by means of 
classical and modern molecular analyses using human leukeamia HL-60 cells.  
It has been proven that heavy metal bioaccumulation of P. pachyphloeus was at nontoxic level 
for human cell lines and played no role on activities of this mushroom. The next step towards 
further understanding was determining the anti-proliferative effect of the aqueous extract of 
this mushroom. At certain concentration, aqueous mushroom extract showed no cytotoxic 
effect but anti-proliferative effect due to induction of apoptosis. Strikingly, our findings 
indicate that aqueous extract of P. pachyphloeus induces apoptosis in HL-60 through the 
activation of the caspase cascade through both death receptor pathway and mitochondrial 
pathway.  
The molecular mechanisms responsible for anti-tumour and immune-stimulatory properties in 
human leukaemia cell line HL-60 upon treatment with aqueous extract of P. pachyphloeus 
were further elucidated. The expression of many apoptotic/anti-apoptotic regulatory proteins 
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has been also ascertained by using proteomics. We also figured out the significant changes in 
miRNA expression due to our treatment. 
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VI. ZUSAMMENFASSUNG 
 
Obwohl es bereits verschiedene Möglichkeiten der Behandlung von Krebs gibt, wird immer 
noch nach neuen, sichereren und effektiveren Methoden gesucht. Eine Reihe von neuen 
antitumoralen Substanzen wird aus der östlichen Medizin und Ethnopharmakologie 
entwickelt. Neben den Pflanzen stellen vor allem die Pilze eine wichtige Quelle von 
bioaktiven Substanzen für die Entwicklung von Therapien in der pharmazeutischen Industrie 
dar. Zurzeit fokussiert sich die Forschung von biologisch aktiven Metaboliten aus Pilzen, die 
in Wasser – sowie Ethanol – löslichen Extrakten enthalten sind. Obgleich viele 
pharmazeutische Eigenschaften, insbesondere die anti-Tumoraktivität von einigen 
medizinischen Pilzen intensiv untersucht wurden, fehlen wissenschaftliche Untersuchungen 
zu den molekularen Mechanismen der Pilzwirkung. Viele Publikationen zeigen, dass die 
biologisch aktiven Substanzen aus Pilzen in Tumorzelllinien die Aktivierung der 
mononuklearen Zellen, die Hemmung der Zellproliferation sowie die Cytokine-Expression 
stimulieren, die Zellteilung regulieren und Apoptose induzieren. Es fehlen aber 
Standardtisierungen und Untersuchungen auf molekularem Niveau.  
In der vorliegenden Arbeit wurde ein tropischer, holzzerstörender Pilz Phellinus 
pachyphloeus (Pat.) Pat. unter Verwendung klassischer und moderner molekularer Analytik 
auf seine Wirkung auf die Leukämiezelllinie HL-60 untersucht. Zunächst wurde festgestellt, 
dass die Bioakkumulation von Schwermetallen durch Phellinus pachyphloeus keinen 
negativen Einfluss auf die menschliche Zelllinie hat. 
Im nächsten Schritt wurden die antiproliferativen Effekte der bioaktiven Komponenten aus 
Wasserextrakten dieses Pilzes untersucht. Dosis-Wirkungsversuche bestätigten eine 
antiproliferative Wirkung der bioaktiven Pilzextrakte. Diese wurde als apoptotischer Effekt 
eingegrenzt. Unsere Ergebnisse zeigten, dass die Wasserextrakte aus Phellinus pachyphloeus 
keinen cytotoxischen sondern einen apoptotischen Effekt in humanen Leukämiezellen 
induzieren könne. Die induzierte Apoptose erfolgte sowohl über den äußeren, Rezeptor-
vermittelten, als auch den mitochondrialen Signalweg.  
Der Einfluss der Extrakte von Phellinus pachyphloeus auf menschliche Zellen wurde 
hinsichtlich antitumoraler und immunstimulierender Wirkung weiter evaluiert. Dabei wurden 
unter Verwendung von 2D-Proteingel-Elektrophorese Veränderungen in der Expression 
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Apoptose-relevanter Proteine gefunden. Darüber hinaus wurden damit korrelierende 
Veränderungen in der Expression regulatorischer miRNAs festgestellt.  
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